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Central Disorders of Hypersomnolence 
 
Sleepiness is a common experience, with estimated prevalence of excessive daytime sleepiness 
(EDS) in general population ranging from 4% to 21%.
1
 
For many of these individuals, such sleepiness may be simply caused by poor sleep habits, illicit 
and prescribed substances, work and family demands (including shift work), or self-imposed sleep 
times that are not sufficient to maintain alertness throughout the day. For others, daytime sleepiness 
may be related to a more serious medical condition. 
Central disorders of hypersomnolence are a group of neurological characterized by EDS in the 
absence of disrupted nocturnal sleep or circadian rhythm disorders.
2
 
According the most recent version of the International Classification of Sleep Disorders, Third 
Edition (ICSD-3), three persistent hypersomnolence disorders are not associated with another 
medical conditions or substance abuse: narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and 
Idiopathic Hypersomnia (IH).
2
 
NT1 was the first of these disorders to be comprehensively described, dating back to a case 
published in 1880 by Jean Baptiste Gélineau.
3
 
The classic symptoms of NT1 are EDS, cataplexy (sudden and transient loss of muscular tone 
usually evoked by emotions), dissociated rapid eye movement (REM) sleep manifestations such as 
sleep paralysis (temporary inability to move voluntary muscles) and/or hallucinations at the wake-
sleep transition, and nocturnal sleep disruption.
2
 
EDS is the cardinal symptom, and often the most disabling. Patients with narcolepsy type 1 
experience repeatedly episodes of an irrepressible need to sleep or lapses into sleep. Most patients 
awaken refreshed after a sleep episode but begin to feel sleepy again after variable times.
2
 
NT1 is also characterized by disordered regulation of rapid-eye-movement (REM) sleep. REM 
sleep normally occurs only during the usual sleep period and includes vivid, story-like dreams, 
rapid (saccadic) eye movements, and paralysis of nearly all skeletal muscles, except the muscle of 
6 
 
respiration. REM sleep can occur in persons with NT1at any time of day, and the classic elements 
of REM sleep often intrude into wakefulness, creating peculiar intermediate states.
4
 
Cataplexy is the most dramatic of the dissociated REM sleep–like states presented by NT1 patients 
and is defined as the sudden loss of muscle tone in response to a strong emotion, usually laughing.
5
 
Typical cataplexy is present in 65% to 75% of individuals with NT1 and is quite specific, only 
rarely cataplexy or cataplexy-like episodes will occur in other disorders (including Coffin-Lowry 
syndrome, Norrie disease, and Niemann-Pick disease type C).
6
 The presence or absence of 
cataplexy is a key distinguishing feature between the two types of narcolepsy, which are now 
recognized to be quite different entities despite their similar nomenclature.
2,7
 
NT1 is caused by the loss of hypothalamic neurons that produces hypocretin, a wakefulness-
associated neuropeptide.NT1 patients have reduced or absent levels of hypocretin-1 (hcrt-1) in their 
cerebrospinal fluid (CSF), accordingly the disease is further classified into NT1 (with hypocretin-1 
deficiency and cataplexy) and Narcolepsy Type 2 (NT2), where cataplexy is absent and hypocretin 
levels are usually in the normal range.
8,9
 
Idiopathic hypersomnia (IH) was detailed by Bedrich Roth in a series of 642 patients seen over 30 
years.
10
 IH is characterized by EDS in absence of dissociated REM sleep manifestation and 
cataplexy, and have a clinical presentation more similar to narcolepsy type 2 than type 1.
11
  
Most patients with IH  feel unrefreshed after naps, which are usually long and in contrast to NT1 
usually present high sleep efficiency (≥90%).12 IH patients report great difficulty with awakening, 
experiencing a prolonged state in which motor functions return before full awareness or there is 
partial return of both after awakening. CSF hypocretin-1 concentrations in patients with IH are 
normal.
2,8
 
 
Epidemiology 
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The prevalence of narcolepsy type 1 is 0.025% to 0.05%.
13
 Globally, the prevalence varies from 
highest in Japan (0.16%) to lowest in Israel (0.0002%).
14
 The age of onset in clinical populations 
appears to be bimodal, with the first peak at 15 years and the second at 35 years.
15,16
 
The exact prevalence of narcolepsy type 2 is uncertain.
2
 Cases of narcolepsy without 
cataplexy represent 15% to 25% of the clinic narcoleptic population. The age of onset mirrors that 
of narcolepsy type 1.Prevalence and incidence of IH are not known. Some studies have suggested a 
higher prevalence in women. The age of onset of IH symptoms ranges from the late teens to 35 
years of age.
2
  
 
Pathophysiology 
 
The neuropeptide hypocretin (also called orexin) was first identified in 1998.
17,18
 
Hypocretin is produced in the lateral hypothalamus and is involved in the regulation of feeding, 
stress response, reward, and the autonomic nervous system. 
Cerebrospinal fluid (CFS) hypocretin-1 levels are reduced in the majority (90%-95%) of subjects 
with narcolepsy and typical cataplexy.
19
 While loss of hypocretin neurons is also seen in 10% to 
30% of cases of narcolepsy type 2, most patients with NT2 have normal hypocretin levels.
8
  
The loss of hypocretin and development of narcolepsy type 1 involves both genetic and 
environmental factors, likely resulting from an autoimmune attack on hypocretin 
neurons in genetically susceptible individuals. The clear genetic predisposition is seen in the 10 to 
40 times higher risk of narcolepsy in first-degree relatives of patients.
20
 
Human leukocyte antigen (HLA) DQB1*06:02 is present in > 85% to 95% of patients with typical 
cataplexy but is not specific, since it is also present in 40% of cases of type 2 narcolepsy and 24% 
of healthy control subjects.
21
 
Despite this apparent genetic predisposition to narcolepsy, concordance rates in identical twins are 
only 25% to 31%, implicating substantial environmental or stochastic factors.
19
  
8 
 
The combination of HLA association, genetic polymorphisms in immune genes, and apparent 
triggering of disease by infection or vaccination all suggest an autoimmune basis for hypocretin-
deficient narcolepsy, that however has yet to be conclusively demonstrated. 
The pathophysiology of narcolepsy type 2 and IH are not yet known. A familial component has 
been proposed in IH, as a family history of EDS is commonly reported by patients.
22
 
The HLA DQB1*0602 allele implicated in narcolepsy has been shown to be increased 
in IH patients in some, but not all studies. IH is rarely caused by hypocretin deficiency,  
 supporting the concept of different pathogeneses of central disorders of hypersomnolence.
18
 
 
Differential Diagnosis 
 
Given these overlapping clinical features, the diagnosis of central disorder of hypersomnolence 
requires attention to both clinical presentation and sleep laboratory test, especially the multiple 
sleep latency test (MSLT).
23
 
The MSLT consists of five 20-min nap opportunities at 2-h intervals. A nocturnal polysomnography  
(PSG) immediately prior the MSLT is mandatory to ensure a sufficient amount of sleep (> 6 h) and 
to rule out other sleep disorders, and sleep logs and/or actigraphy in the two week before to 
document regular sleep timing and duration and to rule out insufficient sleep. 
Two parameters of most interest are the mean sleep latency (MSLT-sl) and the number of sleep-
onset REM periods (SOREMPs). The sleep latency is the first epoch of sleep (any stage), and the 
MSLT-sl is the mean across all naps. A SOREMP is the presence of at least one epoch 
of REM during a nap opportunity. The MSLT is a major factor in current classification of patients 
with central disorders of hypersomnolence: the number of SOREMPs determines whether a patient 
with clinical complaints of hypersomnolence is classified as having narcolepsy (if they have two or 
more SOREMPs) or if they have IH (if they have fewer than two SOREMPs).
24
 
9 
 
Despite being the gold standard for the diagnosis of narcolepsy, like most diagnostic modalities, it 
is not without flaws. First, MSLT-sl and SOREMPs are specific since up to 30% of the normal 
population may have a MSLT-sl ≤8 min, the current cut-off for the hypersomnolence 
disorders. Second, the MSLT may not be adequately sensitive for IH; the 8-min cutoff was 
determined for patients with narcolepsy and extended to IH for “simplicity,” without independent 
determination.
25 
Third,  the subjective experience of sleepiness (indexed by the Epworth Sleepiness 
Scale - ESS) correlates only modestly with MSLT-sl. Optimal diagnostic methods for IH require 
further study. 
 
Diagnostic delay 
 
Despite being one of the most common causes of chronic sleepiness, affecting about 1 in 2000 
people, narcolepsy may remain undiagnosed in as many as half of all affected people with 
narcolepsy, since many clinicians are unfamiliar with this disorder.
26,27
 
Usually there is a long interval from the onset of symptoms before a diagnosis is made.
 
The 
symptoms often start in the second or third decades of life and new symptoms can develop over 
many years. Delays between the first symptom and diagnosis have been reported to range from 1 to 
60 years, with a mean delay of between 16 and 22 years.
28 
 Patients with a more recent onset of 
symptoms have been reported to have a shorter interval before they were diagnosed compared to 
those whose symptoms started further in the past. 
A number of factors to see if they were associated with a delay in diagnosis, among all the lack of 
any reliable screening tool.
28,29
 
Several tool has been proposed ranging from questionnaire, to biological marker, however none of 
them seem suitable for screening large-population. To date this research question still remains open 
and is crucially important for the quality of life of this clinical population. 
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Cognitive impairments 
 
Narcolepsy significantly interferes with several aspects of daily life, wielding negative social and 
professional impacts that may considerably affect the quality of life.
30
 
A great portion of patients complain about attention and memory problems, and those problems are 
presumably responsible for a wide variety of difficulties in everyday life, such as problems at 
school and home and difficulties to obtain and maintain employment.
31
 
These have led several investigators to question whether an underlying cognitive impairment might 
accompany the classical symptoms of NT1.
32
 
Evidence for genuine cognitive impairment in narcolepsy is scarce and sometimes contradictory. 
Standardized empirical investigations of memory abilities yielded intact or only modestly impaired 
short- and long-term memory in narcoleptics patients.
33,34
 
In the area of attention, different studies showed that patients with narcolepsy have slower reaction 
times (RTs) than controls, even in relatively simple tasks.
35
 It is also frequently reported, that 
performance in patients with narcolepsy is more variable than in controls.
36
 
Nonetheless, in spite of the relevance of the dual disturbance of vigilance and sleep, the most 
commonly used tests to measure the burden of narcolepsy focus solely on the tendency to fall asleep 
(MSLT) and the ability of stay awake (Maintenance of Wakefulness Test-MWT).
23
  
Identifying and implement objective neuropsychological tests, which may show results deviating 
from the patient’s individual impression, should be implemented in the routine diagnostic 
evaluation. 
 
Aims 
In this dissertation, we aimed to: 
 
A) Identify behavioral biomarker for Type 1 Narcolepsy, able to screen large at risk-population. 
11 
 
B) Evaluate attentional performances of patients with Type 1 and Type 2 Narcolepsy, compared to  
healthy controls. 
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ABSTRACT 
 
Objective. To evaluate the reliability of actigraphy to distinguish the features of daytime and 
nighttime sleep between patients with central disorders of hypersomnolence and healthy controls. 
Methods. Thirty-nine drug-naïve patients with Narcolepsy Type 1, twenty-four drug-naïve patients 
with Idiopathic Hypersomnia and thirty age- and sex- matched healthy controls underwent to seven 
days of actigraphic and self-report monitoring of sleep/wake behavior. 
The following variables were examined: estimated time in bed (TIB), estimated total sleep time, 
estimated sleep latency (SOL), estimated sleep efficiency, estimated wake after sleep onset, number 
of estimated awakenings (Awk), number of estimated awakenings longer than 5 minutes, estimated 
sleep motor activity (SMA), number of estimated naps, mean duration of the longest estimated nap 
(NapD) and daytime motor activity.  
Results. All actigraphic parameters significantly differentiated the three groups, except estimated 
TIB and estimated SOL. A discriminant score computed combining actigraphic parameters from 
nighttime (estimated SMA, estimated Awk) and daytime (estimated NapD) periods showed a wide 
area under the curve (0.935) and a good balance between positive (95%) and negative predictive 
(87%) values in Narcolepsy Type 1cases. 
Conclusion. Actigraphy provided a reliable objective measurement of sleep quality and daytime 
napping behavior able to distinguish central disorders of hypersomnolence and in particular 
Narcolepsy Type 1. The nycthemeral profile, combined with a careful clinical evaluation, may be 
an ecological information, useful to track disease course.  
 
Keyword: Actigraphy, Narcolepsy Type 1, Idiopathic Hypersomnia, nycthemeral profile, motor 
activity 
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INTRODUCTION 
 
Narcolepsy Type 1 (NT1) and Idiopathic Hypersomnia (IH) are two central disorders of 
hypersomnolence characterized by chronic sleepiness not explained by altered nocturnal sleep or 
sleep deprivation.
1
 Although hypersomnolence features may overlap in IH and NT1, these disorders 
display distinct clinical, neurophysiological and biochemical presentations.
2
 
NT1 is characterized by daytime and nighttime symptoms: daytime sleepiness (hypersomnolence), 
with sleep attacks characterized by direct transitions into rapid eye movement (REM) sleep (sleep-
onset REM periods - SOREMPs); cataplexy (sudden loss of muscle tone triggered by emotions), 
sleep paralyses and hallucinations, and disrupted nighttime sleep.
1,3
 Patients with NT1, indeed, 
present a nighttime sleep interrupted by numerous and prolonged awakenings, and also abnormal 
simple movements (e.g. nocturnal myoclonus) or complex behaviors (e.g. parasomnias) during both 
REM and non-REM sleep.
4 
Conversely, IH is characterized by hypersomnolence and nocturnal 
sleep with normal features and, possibly, long duration.
1,5 
Nocturnal sleep and hypersomnolence are usually explored through nocturnal polysomnography 
(PSG) and multiple sleep latency test (MSLT) respectively. MSLT is the gold standard laboratory-
based measure of daytime sleep propensity, currently used worldwide as main diagnostic tool for 
the differential diagnosis among central disorders of hypersomnolence.
6,7
  
Recently, several studies attempted a more naturalistic approach by comparing the features of 
spontaneous daytime sleep at 24-hour continuous polysomnography versus MSLT results, in the 
context of central disorders of hypersomnolence.
8,9
 These studies emphasized the utility of 
prolonged recordings performed under conditions more similar to usual life habits of patients. 
Nevertheless, 24-hour recordings are difficult to apply to clinical practice. 
Actigraphic monitoring has become, over the last two decades, a widely used assessment tool in 
sleep medicine to continuously document several nycthemeral cycles, barely interfering with a 
subject’s daily routine. 10,11 
17 
 
According to the current International Classification of Sleep Disorders 3
nd
 edition (ICSD-3), 
actigraphy plays a major role for the objective monitoring of sleep schedule and duration in the 
weeks prior to MSLT in central disorders of hypersomnolence, in order to objectively rule out 
insufficient sleep or circadian rhythms misalignment.
1 
Actigraphic studies on central disorders of 
hypersomnolence are rare, and the above ICSD-3 recommendations were mostly due to 
consensus,
12
 although preliminary data are of interest: Middelkoop and co-authors compared the 
circadian pattern of motor activity of 14 drug-free NT1 patients versus age- and sex- matched 
controls, and demonstrated that diurnal and nocturnal measures of “uninterrupted immobility” 
(defined as mean duration of periods without activity) were able to discriminate between groups, 
with NT1 patients showing a higher nocturnal motor activity profile.
13
 More recently, Bruck and co-
authors confirmed those findings, even though in a small cohort of NT1 patients (n = 9). 
Additionally, the authors showed that the actigraphic measurement of “immobility” could be 
successfully used to differentiate between medicated and unmedicated NT1 patients treated with 
wake-promoting medication.
14
 Finally, Poryazova and co-authors showed that actigraphic estimated 
sleep quality significantly improved after treatment with sodium oxybate, suggesting that actigraphy 
could offer a cheaper and simpler alternative to PSG for assessing sodium oxybate treatment 
effects.
15
       
The purpose of this study was to determine if actigraphy can reliably characterize the circadian 
profile of sleep and wakefulness of different central disorders of hypersomnolence and distinguish 
NT1 from IH patients and healthy controls by combining diurnal hypo-activity (as index of 
hypersomnolence) and nocturnal hyper-activity (as index of disrupted sleep quality) measures.  
 
MATERIAL E METHODS  
 
Subjects 
 
18 
 
Subjects were patients evaluated for complaints of hypersomnolence, from March 2010 to January 
2014, at the outpatient clinic for Narcolepsy of the Department of Biomedical and Neuromotor 
Sciences, University of Bologna, and who received a final diagnosis of central disorders of 
hypersomnolence according to the ICSD-3 criteria.
1
 
All patients underwent the following diagnostic protocol: (a) clinical evaluation performed by the 
same sleep specialist (G.P.); (b) assessment of subjective sleepiness by means of Italian version of 
the Epworth Sleepiness Scale (ESS);
16
 (c) seven days of actigraphic and self-report monitoring of 
sleep-wake behavior; (d) 48-hour continuous polysomnographic recording followed by (e) a MSLT 
with five nap opportunities; and (f) lumbar puncture to assay hypocretin-1 levels, where possible.  
The final study sample included 63 patients, consisting of thirty-nine NT1 patients (22 males, mean 
age 34 ± 16 years) and twenty-four IH patients (11 males, mean age 32 ± 15 years). All patients 
were drug-naïve at the time of actigraphic recording. 
NT1 patients fulfilled the ICSD-3 criteria presenting: persistent daytime sleepiness (ESS score 
16.41 ± 3.42), a clear-cut history of cataplexy (n = 39/39), and mean sleep latency <8 min (mean 
3.14 ± 1.77) with at least two sleep-onset REM periods (mean 3.92 ± 1.10) at the MSLT. All 
patients were HLA DQB1*0602 positive and had reduced (i.e. < 110 pg/ml) or undetectable 
hypocretin-1 levels (mean 26.70 ± 27.72) when tested (n = 24/39).  
IH diagnosis required the following criteria according to current ICSD-3: presence of persistent 
daytime sleepiness (ESS score 14.50 ± 3.57), absence of cataplexy, mean sleep latency <8 min 
(mean 6.14 ± 1.09) with fewer than two SOREM at MSLT (mean 0.38 ± 0.49) and nocturnal PSG, 
adequate schedule and duration of the main sleep period documented by actigraphy (estimated total 
sleep time = 417 ± 75 min.), and no evidence of concurrent sleep or medical disorder as stated by 
nocturnal PSG and clinical evaluation respectively. CSF hypocretin-1 concentration was in the 
normal range (i.e. > 200 pg/ml) in all patients tested (n = 11, mean 335.55 ± 138.03); four patients 
were HLA DQB1*0602 positive (16.6 %). 
19 
 
Thirty healthy controls (15 males, mean age 29 ± 9 years) were recruited from the local community. 
Participants were clinically screened to rule out sleep or medical disorders; only subjects with 
regular sleep schedule and without complaints of sleep disturbance or daytime sleepiness (mean 
ESS score 4.47 ± 2.63) were included. 
The study was approved by the local review board and all participants signed a written informed 
consent. 
 
Actigraphic assessment 
 
Actigraphy is based on small wrist-watch like devices that monitor movements for extended periods 
of time. Actigraphy is a semi quantitative method, provides an indirect assessment of sleep through 
the use of computerized scoring algorithms applied to the raw activity data. 
The Micro Motionlogger
® 
Watch actigraph (Ambulatory Monitoring, Inc., Adrsley, NY) was used 
in the present study. The hardware consists of a triaxial accelerometer; overall sensitivity is 0.01g at 
the midpoint of bandpass filter which is set at 2-3 Hz, and sampling frequency is set at 32 Hz. This 
device has also a temperature and an ambient light sensor. Actigraphs were initialized in zero 
crossing mode to collect data in 1-min epochs. The raw activity data were analyzed through 
ActionW-2 version 2.7.1 software using the mathematical model validated by Cole and co-
authors.
17
. The algorithm computes a weighted sum of the activity in the current epoch, the 
preceding 4 epochs, and the following two epochs as follows: S = 0.0033 (1.06a-4 + 0.54a-3 + 0.58a-2 
+ 0.76a-1 + 2.3a0 + 0.74a1 + 0.67a2); where from an4 to an1 are the activity counts from the preceding 
4 minutes, a1 and a2 are activity counts from the following 2 minutes, and a0 is the current epoch 
that is scored as sleep when S < 1.   
  Participants were asked to wear the actigraph on the non-dominant arm over seven consecutive 
days, starting at the clinic visit, which are sufficient to obtain a meaningful description of the rest-
activity behavior.
18
 Subjects were instructed to maintain their habitual sleep/wake schedule during 
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the recording period. Parallel to actigraphic assessment, subjects were asked to fill out a daily sleep 
log in which they would report: (i) what time they went to bed at night and their last awakening in 
the morning, and (ii) frequency and duration of diurnal naps. Moreover, subjects were instructed to 
push a button located on the side of the watch (“event marker”) to mark occurrences such as time in 
and out of bed and periods when the actigraph was not worn. Using both event-marked points and 
sleep log information, scoring was checked in order to identify sleep-wake periods and eliminate 
periods when actigraph was removed. 
 
Nighttime and daytime measures 
 
For nighttime period, corresponding to the time between when the subject went to bed and switched 
off the light and final self-reported awakening in the morning, we considered the following 
actigraphic measures: estimated time in bed (TIB – time in minutes, between reported light off and 
light on), estimated total sleep time (TST – sum, in minutes, of all sleep epochs between light off 
and light on); estimated sleep onset latency (SOL – interval in minutes, between light off and sleep 
onset); estimated sleep motor activity (SMA – mean number of movements within one minute, 
during sleep epochs); estimated  wake after sleep onset (WASO – sum, in minutes, of all wake 
epochs between sleep onset and sleep end); estimated sleep efficiency (SE%, the ratio of TST to 
TIB multiplied by 100); estimated wake episodes (Awk – number of epochs scored as wake 
between sleep onset and sleep end) and number of estimated wake episodes lasting more than 5 
consecutive epochs (Awk>5). 
For the daytime period, corresponding to the time between the final self-reported awakening in the 
morning and the beginning of a new major sleep period, we considered the following actigraphic 
measures: daytime motor activity (DMA – mean number of movements within one minute, during 
estimated wake period); number of estimated sleep episodes lasting more than 5 consecutive epochs 
21 
 
(Nap); and mean duration of longest estimated sleep episodes (NapD – mean duration, in minutes, 
of the longest estimated sleep episodes). 
 
Statistical analyses 
 
Data for each group were explored using descriptive statistics (mean ± SD). Group differences in 
demographic and clinical data were analyzed with Pearson's chi-square test for categorical 
variables, Mann-Whitney test for ordinal data, and one-way between-group analysis of variance 
(ANOVA) for continuous variables. 
Comparisons of actigraphic variables were performed by means of ANOVA, post-hoc comparisons 
were performed using Bonferroni test. 
A stepwise multiple discriminant analysis with Wilks' s Lambda method was carried out to explore 
whether a set of variables is more effective in predicting group membership; F values of 3.84 for 
entry into, and 2.71 for removal from, the discriminant analysis were used. The first discriminant 
function selected was applied to the data and a receiver operating characteristic (ROC) curve was 
generated.
19
  
Values of the Area under ROC curves were used to select cut-off values; the Youden Index (i.e. the 
higher value obtained calculating sensitivity+specificity-1) was used to determine optimal cut-off 
values, finally positive and negative predictive values were computed.
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All statistical analyses were performed using SPSS 19.0 (SPSS, Inc. Chicago, Ill). P-value <0.05 
was considered statistically significant. 
 
RESULTS 
 
Chi-square and one-way ANOVA analyses revealed no differences among groups in either gender 
or age, respectively. One-way ANOVA showed no difference between NT1 and IH regarding levels 
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of subjective sleepiness, while both clinical groups displayed higher ESS score than controls, as 
expected for inclusion criteria (p < 0.0001). Demographics, clinical, MSLT and biochemical data 
for all subjects are shown in Table 1. Overall the wearing time of the actigraphic device exceed  
90% of the total recording time (mean values 95.40 ± 2.73%, range 90.21-99.13%). 
Actigraphic nighttime and daytime data for the three groups are reported in Table 2, together with 
significance values of the ANOVA and post-hoc results. Results showed a main group effect for all 
actigraphic parameters considered except estimated TIB and estimated SOL. Post hoc contrast 
disclosed that: (a) NT1, IH and controls spent in bed the same amount of time, but NT1 patients 
slept significantly less than both IH and controls; (b) NT1 patients had the lowest estimated SE% 
with more time spent in estimated WASO than the other two groups; (c) NT1 patients showed the 
highest frequency of estimated nocturnal awakenings, followed by IH and controls respectively 
(NT1 > IH > Controls); (d) estimated nighttime motor activity levels of NT1 patients were 
significantly higher than those of IH and controls; (e) daytime motor activity levels of NT1 and IH 
patients were significantly reduced than those of controls; and (f) NT1 patients showed the highest 
frequency of daytime estimated naps, followed by IH and controls respectively. The same trend of 
differences was observed regarding average duration of the estimated longest nap (NT1 > IH > 
Controls). Stepwise discriminant analysis was performed including all variables that significantly 
differed among groups in the ANOVA. 
 The first function selected included three predictors estimated SMA, estimated Awk and estimated 
NapD that accounted for 97% of the explained between-group variance (Wilks Lambda = 0.292, p = 
0.0001, Eigenvalue = 2.228) and was computed as Discriminant Score (DS): 
SMA*0.049+Awk*0.095+NapD*0.04-2.934. Overall, this linear function correctly classified  
81.7% of the cases. More in detail, classification accuracy was 87.2% for NT1 (n = 34/39), 58.3% 
for IH (n = 14/24), and 93.3% for healthy controls (n = 28/30) respectively. At ROC curve analysis, 
DS showed an area under the curve of 0.935 (Figure 1); using a balanced approach, a cut-off of 
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mean DS equal to -1.05 produced a good balance between positive (0.95) and negative (0.87) 
predictive values.  
 
DISCUSSION 
 
This study was the first to investigate the actigraphic estimated daytime and nighttime sleep in a 
group of drug-naïve patients with different central disorders of hypersomnolence (namely NT1 and 
IH) and in healthy controls. Altogether, our findings showed that NT1 patients displayed a 24-hour 
actigraphic profile characterized by nighttime and daytime impairment, while IH patients displayed 
a daytime impairment without differences in overall estimated sleep quality when compared to 
healthy controls. The discrete daytime and nighttime actigraphic profile of patients suffering from 
central disorders of hypersomnolence suggests that actigraphy may provide useful information 
when combined with a careful clinical examination, and can also possibly distinguish among 
groups. Analyzing nighttime period we found that NT1 patients presented a marked decrease in 
estimated sleep quality, which was characterized by reduced total sleep time with numerous 
estimated awakenings, extended time spent in estimated WASO and high representation of motor 
events, when compared with IH patients and controls. Conversely, patients with IH showed higher 
frequency of estimated nocturnal awakenings when compared with controls, without any other 
between-group difference. These results are in line with PSG studies in documenting the features of 
disrupted nighttime sleep in NT1.
4,21
 Noteworthy, levels of nocturnal motor activity rendered a 
different pattern in NT1, further confirming that an increased motor activity during nightsleep is an 
intrinsic feature of this disease.
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Loss or impaired hypothalamic hypocretin (HCRT) signaling may, at least in part, explain the 
nighttime motor dysfunction of NT1 patients.
23
 Hypocretin axons are found throughout the brain 
with dense projections to brainstem nuclei and to basal forebrain regions; under typical conditions 
hypocretinergic neurons promote motor activity during wakefulness and inhibit motor activity 
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during REM sleep.
24
 In patients with NT1 the opposite seems to take place, with motor inhibition 
and sleep occurring during the major wakefulness period, as well as enhanced muscle tone and 
motor activity during sleep.
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During daytime patients with NT1 and IH present a more scattered distribution of estimated naps 
and a reduction in mean motor activity levels when compared to healthy controls. The nature and 
severity of diurnal impairment, however, differed among IH and NT1, with NT1 patients displaying 
highest estimated nap frequency and lowest motor activity level. 
 Our results confirm earlier studies that, however, considered different actigraphic variables (i.e. 
immobility) and tested smaller groups of narcoleptic patients, reporting a trend in difference 
between NT1 and controls regarding the diurnal period.
13,14 
In addition, by comparing patients with 
NT1 and IH, we extended these findings to other central disorders of hypersomnolence with 
comparable levels of subjective sleepiness, pinpointing that actigraphy may contribute to reliably 
render the features of daytime behavior in different central disorders of hypersomnolence. Overall, 
we found that the actigraphic nycthemeral profile is able to reliably differentiate among groups. 
Moreover, it can be useful, in combination with PSG and MSLT, in both the diagnostic work-up of 
central disorders of hypersomnolence and in the follow-up as objective measures of disease course 
and treatments efficacy.  
Noteworthy, we found that the combined use of both nocturnal (estimated SMA, estimated Awk) 
and diurnal (estimated NapD) parameters performed better in NT1 cases than any single actigraphic 
measure. Indeed, these parameters reflect two intrinsic features of NT1, namely disrupted nocturnal 
sleep (estimated Awk, estimated SMA) and hypersomnolence (estimated NapD).  
Some limitations of the present study should be acknowledged. First, although reporting on the 
largest actigraphic evaluation on NT1 patients in the literature, we are still underpowered to stratify 
the findings by different age groups. Second, some cautions need to be used in interpreting the 
diurnal motor activity data since DMA levels are clearly influenced by the scattered distribution and 
duration of sleep episodes during daytime. Future studies using chronobiological approach may 
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help to establish whether the decrease in DMA levels still persists despite the elevated frequency of 
diurnal sleep episodes. 
Overall, the present study shows that actigraphic monitoring is a useful technique to objectively 
assess the features of sleep-wake profile of central disorders of hypersomnolence, with the main 
advantage of providing more naturalistic information. Further studies are needed to explore whether 
the actigraphic measurements considered are sensitive enough to detect treatment effects on both 
nighttime and daytime sleep. 
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Table 1 – Demographic characteristics, scale scores and MSLT data of patients with narcolepsy type 1, idiopathic hypersomnia, and 
healthy controls. 
                                            
Narcolepsy Type 1 Idiopathic Hypersomnia   Healthy Controls   
  
  n = 39 n = 24 n = 30   
Demographic and clinical data  mean ± SD (%) mean ± SD (%) mean ± SD  P-value
a
 
       
Age, years 34.21 ± 15.58 31.96 ± 15.20 29.37 ± 9.47 0.38 
Male gender 23 11 15 0.56 
BMI 27.20 ± 5.62 24.78 ± 4.43 22.79 ± 2.81 <0.001 
ESS score 16.41 ± 3.42 14.50 ± 3.57 4.47 ± 2.63 <0.0001 
CSF hypocretin-1  26.70 ± 27.72 335.55 ± 138.03  <0.0001 
HLA DQB1*0602 positive 39 (100) 4 (16.6)  <0.0001 
MSLT data 
    MSLT sleep latency, minutes 3.14 ± 1.77 6.14 ± 1.09  <0.0001 
    SOREMs, numbers 3.92 ± 1.10 0.38 ± 0.49   <0.0001 
BMI = body mass index; ESS = Epworth sleepiness scale;  MSLT = multiple sleep latency test; SOREMP = sleep-onset REM period. 
Data are presented as mean ± SD or number (percentage). Data were based on total number of subjects in each group, except CFS 
hypocretin-1, which included data from 24 (NT1) and 11 (IH) subjects, respectively. 
a
P-values were derived from One-way ANOVA, Chi-square test or Mann-Whitney U test, as appropriate. 
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Table 2 – Actigraphic measures (Means and SD) and post-hoc results for NT1, IH and Control group. 
 
NT1 Group 
(n=39) 
IH Group 
(n=24) 
Control Group  
(n=30)   
NT1 vs 
Control 
NT1 vs 
 IH 
IH vs Control 
Mean ± SD Mean ± SD Mean ± SD P-value 
post-hoc/ 
t-test 
post-hoc/ 
t-test 
post-hoc/ 
t-test 
Nighttime period        
TIB (min.) 471.04 ± 65.13 465.07 ± 85.59 478.82 ± 59.69 ns    
TST (min.) 362.57 ± 83.49 417.41 ± 74.73 457.97 ± 53.04 <0.00001 0.0001 0.01 ns 
SOL (min.) 13.29 ± 13.34 11.53 ± 9.73 8.32 ± 4.68 ns    
SE (%) 76.97 ± 13.97 89.65 ± 5.34 95.70 ± 1.99 <0.00001 0.0001 0.0001 ns 
WASO (min.) 92.50 ± 55.17 36.46 ± 26.68 12.49 ± 8.80 <0.00001 0.0001 0.0001 ns 
Awk (n°) 17.13 ± 6.90 11.95 ± 6.63 3.47 ± 2.13 <0.00001 0.0001 0.005 0.0001 
Awk>5 (n°) 5.18 ± 2.49 2.54 ± 2.10 1.20 ± 0.89 <0.00001 0.0001 0.0001 0.05 
SMA (counts) 29.80 ± 14.25 16.12 ± 6.21 9.98 ± 3.27 <0.00001 0.0001 0.0001 ns 
Daytime period        
DMA (counts) 192.41 ± 30.26 199.14 ± 45.11 222.88 ± 15.94 <0.0005 0.0001 ns 0.05 
Nap (n°) 3.51 ± 1.67 2 ± 2.36 0.5 ± 0.90 <0.00001 0.0001 0.005 0.005 
NapD (min.) 35.46 ± 15.50 19.83 ± 17.38 6.40 ± 11.46 <0.00001 0.0001 0.0001 0.005 
DS 1.57 ± 1.17 -0.22 ± 1.17 -1.86 ± 0.46 <0.00001 0.0001 0.0001 0.0001 
SD – standard deviation; TIB –  estimated  time in bed (min.); TST –  estimated  total sleep time (min.); SOL –  estimated  sleep onset latency 
(min.); SE% –  estimated  sleep efficiency;  WASO –  estimated  wake after sleep onset (min.); Awk – number of  estimated awakenings; Awk>5 – 
number of  estimated awakenings longer than 5 consecutive minutes; SMA – mean  estimated sleep motor activity (number of movements in one 
minute); DMA – mean daytime motor activity (number of movements in one minute); Nap – number of daytime  estimated sleep episodes longer 
than 5 consecutive minutes; NapD – mean duration of longest  estimated sleep episode (min.); DS – discriminant score.  
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Figure 1 – Receiver operating characteristic curve for the combination (DS) of Awk (number of 
estimated awakenings), SMA (estimated sleep motor activity) and NapD (mean duration of longest 
daytime estimated sleep episode) 
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ABSTRACT 
 
Study Objectives: Pediatric type 1 narcolepsy is often challenging to diagnose and remains largely 
undiagnosed. Excessive daytime sleepiness, disrupted nocturnal sleep, and a peculiar phenotype of 
cataplexy are the prominent features. Scarce knowledge are available about the regulation of 
circadian rhythms in affected children. This study compared circadian rest-activity rhythm and 
actigraphic estimated sleep measures of type 1 narcolepsy children versus healthy controls.    
Design: Case-control, rest-activity rhythm was quantified over seven days by actigraphy. 
Setting:  Children studied during the school week. 
Patients or Participants: Twenty-two drug-naïve type 1 narcolepsy children and twenty-one age- 
and sex- matched controls. 
Interventions: N/A. 
Measurements and Results: Circadian activity rhythms were analyzed through functional linear 
modeling; nocturnal and diurnal sleep measures were estimated from activity using a validated 
algorithm. Type 1 narcolepsy children presented an altered rest-activity rhythm characterized by 
enhanced motor activity throughout the night and blunted activity in the first afternoon. No 
difference was found between type 1 narcolepsy children and controls in the timing of circadian 
phase. Actigraphic sleep measures showed good discriminant capabilities in assessing type 1 
narcolepsy nycthemeral disruption. 
Conclusions: Circadian rest-activity rhythm is altered in pediatric type 1 narcolepsy. Recording 
motor activity by actigraphy promises to be a reliable objective marker in the complex diagnostic 
pathway of type 1 narcolepsy in children. This simple and cheap screening could help to improve 
diagnosis, and may prove useful to assess disease severity and reduce diagnostic delay. 
Keywords: Narcolepsy, Pediatrics, Circadian Rhythms, Motor Activity, Actigraphy. 
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INTRODUCTION 
 
Type 1 narcolepsy (NT1) is a lifelong central nervous system disorder characterized by chronic 
hypersomnolence with multiple sleep attacks during daytime, cataplexy (sudden and transient loss 
of muscular tone usually evoked by emotions), dissociated rapid eye movement (REM) sleep 
manifestations such as sleep paralysis (temporary inability to move voluntary muscles) and/or 
hallucinations at the wake-sleep transition, and nocturnal sleep disruption.
1,2
 The disease is linked to 
the loss of hypothalamic hypocretin-producing neurons, which leads to cerebrospinal fluid (CSF) 
hypocretin-1 (hcrt-1) deficiency.
1,3 
NT1 is regarded as rare with estimated prevalence between 25 and 50 per 100.000 in the general 
population,
4
 however a large proportion of the expected cases are undiagnosed or remain 
misdiagnosed in both adults and children.
5,6 
Until recently, NT1 has been poorly recognized in 
children although the majority of the patients report the onset of symptoms in childhood and 
adolescence.
5
 Indeed, scarce epidemiological data on pediatric NT1 are available,
7
 nevertheless the 
improving disease awareness and the recent peak of incidence after H1N1 influenza pandemic and 
vaccine has led to a relevant increase in NT1 diagnoses in children and adolescents.
8,9 
Diagnosis of childhood NT1 remains often challenging, especially close to symptom onset, given 
the frequent paradoxical presentation of hypersomnolence as hyperactivity and the peculiar 
cataplexy phenotype with persistent and spontaneous hypotonic features and falls, intermingled 
with active movements and further enhanced by emotions.
10-12 
 This variable clinical presentation, 
and the still scarce awareness about this peculiar features, has frequently led to misdiagnosis with 
behavioral, psychiatric or neurological disorders, further delaying proper diagnosis and 
treatment.
6,13 
Recently, several studies have highlighted that actigraphy, an objective method for quantitative 
assessment of motor activity and indirect assessment of sleep based on wearable technology, offers 
unique potentialities in the clinical work-up of adult NT1 cases.
14,15
 Actigraphic monitoring 
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discriminated NT1 from other central hypersomnias in patients and healthy controls,
14
 and 
quantified treatment response to wake-promoting drugs and sodium oxybate.
16,17 
Besides sleep assessment,
18 
prolonged actigraphic monitoring also offers a way to evaluate the 
robustness of the endogenous rhythms driven and synchronized by the master circadian pacemaker 
through direct evaluation of rest-activity rhythm.
19 
 To date only a limited number of studies has 
investigated circadian rhythms in NT1, describing increased daytime secretion of melatonin,
20,21
 
while circadian rhythms of core body temperature and cortisol were essentially preserved.
22
 
However, these studies examined exclusively adult patients with a long disease history.
 
The main purpose of the current study is to investigate the rest-activity rhythm in pediatric NT1 
patients versus healthy children by means of actigraphy. Actigraphy is a non-invasive method that 
provides circadian measures collected in the subject's natural environment, thus representing a 
particularly valuable approach to assess rest\activity behavior among pediatric populations.
23,24
 
Furthermore, prolonged actigraphic monitoring allows the extraction of densely recorded time 
series of motor activity suitable to be analyzed with advanced techniques for data modeling.
25
 The 
secondary aim of the study is to compare actigraphic estimated nocturnal and diurnal sleep 
measures of NT1 children with age- and sex- matched controls to explore whether actigraphic 
assessment shows good discriminant capability in pediatric NT1 cases, together with the analyses of 
correlates between clinical (BMI and hcrt-1), neurophysiological and actigraphic-derived sleep 
measures. 
 
METHOD 
 
Subjects  
 
The study included 22 patients, drug-naïve children and adolescents (10 males, mean age 
12.09±2.37 years, range 7-15 years), with a final diagnosis of NT1 evaluated at the Outpatient 
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Clinic for Narcolepsy of the Department of Biomedical and Neuromotor Sciences, University of 
Bologna from January 2012 to September 2013. 
Patients underwent the following diagnostic procedures: clinical assessment, at home actigraphic 
monitoring, cerebral magnetic resonance imaging (to rule out secondary cases), and then 
hospitalization with 48-hr continuous polysomnographic (PSG) recording, multiple sleep latency 
test (MSLT), cataplexy video-documentation, human leukocyte antigen (HLA) typing to confirm 
DQB1*06:02 haplotype and, whenever possible, CSF hcrt-1 assay.
26
  
Clinical evaluation was systematically conducted by the same sleep specialist (G.P.), it included the 
assessment of subjective sleepiness with the Epworth Sleepiness Scale adapted for children and 
adolescents (aESS),
27
and of circadian preferences by means of the Italian version of the reduced 
Morningness-Eveningness questionnaire for Children and Adolescents (rMEQ-CA).
28
   
All patients fulfilled the current ICSD-3 clinical criteria for NT1 presenting severe cataplexy (n = 
22/22) and daytime sleepiness (aESS score: 13.86 ± 3.37). Twenty out of 22 cases had mean MSLT 
sleep latency (MSLT-sl) < 8 min with multiple sleep-onset REM periods (SOREMPs). Seventeen 
patients (including the 2 cases with MSLT-sl > 8 min) underwent lumbar puncture and all had low 
(≤ 110 pg/ml) or undetectable CSF hcrt-1 levels; all patients carried the HLA DQB1*06:02 allele. 
Twenty-one age- and sex-matched healthy children (13 males, mean age 10.95±2.25 years, range 7-
16 years), recruited at a school in Rome, were selected from the anonymous database of the 
Pediatric Sleep University Center, Sapienza University, Rome. This series of children belong to the 
same group of controls used in a previously published study.
29  
The study was approved by the internal review board and written informed consent was signed by 
parents of children. 
 
Procedure  
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Rest-activity rhythm was monitored during the school week, outside of holidays and vacation. 
Participants were required to wear the actigraph on the non-dominant wrist for one week (before 
hospitalization for NT1 patients), providing five complete nycthemeral cycles, which are necessary 
to obtain a reliable description of sleep and rest-activity rhythm in children.
30
 
The Micro Motionlogger
®
 Watch actigraph (Ambulatory Monitoring, Inc., Ardsley, NY), consisting 
of a triaxial accelerometer with case temperature and ambient light sensors, was used in the present 
study. Actigraphs quantify motor activity exceeding 0.01g at a sampling frequency of 32 Hz, the 
values for each sample are used to compute the average activity counts within the chosen time 
window (epoch). Devices were initialized for zero-crossing mode to collect data in one-minute 
epochs in accordance with the practice parameters for the use of actigraphy.
23
 
Participants were asked to maintain their usual sleep/wake schedule during the recording period. 
Children wore the device continuously throughout the 24 hours, except when bathing/showering, 
and were instructed to push the event-marker button on the device to mark time in and out of bed.  
In addition, a sleep diary was used to obtain subjective information from the children, for children 
under 11 years of age (i.e. 5 NT1 and  9 control children) we asked parents/caregivers to  fill in 
daily the sleep diary and help them with the event-marker procedure, if necessary.  
The information contained in the sleep diary included the bedtime, the wake time, and the rise time, 
additionally we asked to record events that might bias the actigraphic recording such as periods of 
device removal. 
Actigraphic recording was visually edited by an experienced scorer who used the information 
provided by event-marker points and sleep dairy to indentify the major nocturnal sleep period. 
Periods of device removal detailed in the diary were further verified from the case temperature 
channel and excluded from analysis. 
 
Circadian rest–activity rhythm and actigraphic sleep assessment 
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For circadian motor activity analysis we extracted raw activity data per minute (time series) using 
Action 4 software version 1.16 (Ambulatory Monitoring, Inc., Ardsley, NY) and processed them 
with R statistical software to apply Functional Linear Modeling (FLM) according to the model put 
forward by Wang and co-authors.
31
 FLM belongs to a broader family of statistical techniques 
(Functional Data Analysis) that represent observations arising from time-series in the form of 
functions.
25,32
 This approach allows the analysis of the circadian features of motor activity through 
direct analysis of raw activity data. FLM replaces the motor activity counts with a function that 
models the data, reduces variability, and compares sets of functions to explore whether and when 
they statistically differ between groups. 
We considered only data from 20:00 Sunday to 20:00 Friday, in order to avoid possible variations 
related to weekend days. Activity gaps during daytime due to device removal were filled up with 
average activity values from the same time-period of the remaining days; days containing gaps 
longer than one hour were excluded from analysis. 
The five continuous nycthemeral cycles of actigraphic data were averaged into a single 24-hour 
motor activity pattern and converted into a function adopting a Fourier expansion model with n = 9 
basis permutation fitted at a 24-hr periodicity. 
Actigraphic estimated sleep measures were computed with the Action W-2
®
 software version 2.7.1 
(Ambulatory Monitoring, Inc., Ardsley, NY), this software identified each epoch as sleep or wake 
using the mathematical model validated by Sadeh.
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Actigraphic recordings were divided into nighttime and daytime periods according to individual 
bedtime and wake-up time; mean daytime and nighttime parameters were computed across the 
school week for each subject. 
We considered the following actigraphic measures for sleep timing: bed time (BT – clock time, in 
hours and minutes, when subject goes to bed and turns off the light), get up time (GUT – clock 
time, in hours and minutes, when subject gets out of bed in the morning), time in bed (TIB – time, 
in minutes, from BT to GUT), and midpoint of sleep (MS – clock time, in hours and minutes, that 
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split in half the TIB). For the nighttime period the following measures were considered: estimated 
sleep onset latency (eSOL – interval, in minutes, between BT and sleep onset, the latter determined 
as the first epoch of a block of 20 consecutive min after BT with no more than one epoch scored as 
wake); estimated total sleep time (eTST – sum, in minutes, of all sleep epochs between sleep onset 
and GUT); estimated wake after sleep onset (eWASO – sum of minutes scored as wake between 
sleep onset and GUT); estimated sleep efficiency (eSE% – the ratio of TST to TIB multiplied by 
100); number of estimated awakenings (eAwk – number of wake episodes between sleep onset and 
GUT); estimated awakenings lasting more than five consecutive minutes (eAwk>5); and sleep 
motor activity (SMA – sum of all activity counts in 1-minute epochs during TIB divided by TIB 
duration in minutes). From the daytime period we considered the following measures: daytime 
motor activity (DMA – sum of all activity counts in 1-minute epochs for the time period between 
GUT and BT divided by its duration in minutes); daytime estimated total sleep time (eDTST – sum 
of minutes scored as sleep between GUT and BT); estimated nap frequency (eNap – number of 
sleep episodes between GUT and BT, where nap is defined as an interval of at least 10 min up to 3 
hours scored as sleep, preceded and followed by a period of at least 30 continuous minutes scored 
as wake); and mean duration of longest estimated nap (eNapD – mean duration, in minutes, of the 
longest daytime sleep episode).  
 
Statistical Analysis 
 
All continuous and categorical data were explored with descriptive (mean ± standard deviation) and 
frequency statistics for each group. Differences between groups in demographical data, BMI and 
scale scores were analyzed with chi-square and independent samples t-test.  
Circadian activity patterns analysis was undertaken with R and the Actigraphy library in R; FLM 
was used to test differences in the time-course of motor activity between groups. 
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For each actigraphic measure independent sample t-tests were performed to compare NT1 and 
control children, followed by effect size (Cohen's d) computation.
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Finally, the relationship between clinical data (BMI and Hcrt-1 levels), questionnaire scores (aESS 
and rMEQ-CA), neurophysiological measures (MSLT-sl and number of SOREMPs), and 
actigraphic-derived sleep measures were explored, separately for each group, with Pearson’s 
correlation coefficient analyses. 
Statistical analyses were conducted using SPSS 19.0 (SPSS, Inc. Chicago, Ill). Results with p 
values <0.05 were considered statistically significant.  
 
RESULTS 
 
Table 1 shows demographic, clinical and neurophysiological characteristics of the sample and 
questionnaire scores. Detailed nocturnal PSG features of the NT1 sample are reported in the 
supplementary table. NT1 patients displayed higher aESS scores and BMI than controls without 
differing in the distribution of circadian typologies or rMEQ-CA scores. 
Circadian mean motor activity profiles of each group resulting from Fourier expansion are shown in 
Figure 1 (upper panel) together with F-statistics results (lower panel). Where the observed statistic 
(i.e., the red solid line) is above the blue dashed line (i.e. global critical test of significance with α = 
0.05) the groups have statistically different activity counts at that specific time point (1 min  
time window). Both groups showed a preserved overall structure, with lower activity during night 
hours and higher activity during daytime, and comparable TIB. NT1 patients had significantly 
higher motor activity throughout nighttime (from 23:00 till 6:00), similar motor activity during 
morning between 7:00 and 12:00, and a significantly marked decrease of motor activity in the 
afternoon starting from 12:00 till about 18:00 with no further differences from the latter time to 
23:00 compared to controls. 
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Actigraphic sleep measures are reported in Table 2, together with significance values at t-test, 
Cohen's d and 95% confidence intervals (CI). NT1 patients and controls went to bed (BT) and woke 
up (GUT) at similar time, thus displaying comparable sleep phase. All actigraphic nighttime 
measures but TIB, eSOL, and sleep timing differed between the two groups: NT1 patients slept less 
during nighttime (eTST), displayed lower eSE% with increased frequency of sleep interruptions 
(eAwk) and prolonged awakenings (eAwk>5), higher amount of eWASO and enhanced SMA than 
controls. During daytime NT1 children had more eDTST with more frequent eNap occurrence, 
longer nap duration (eNapD), and lower motor activity during wakefulness (DMA) than controls. 
Pearson’s correlation analyses are reported in Table 3 for NT1 patients and controls respectively. In 
the NT1 group we found that: (a) BMI was positively correlated with aESS and SMA, and 
negatively with TIB, eTST, eSE%, eAwk and DMA; (b) aESS was directly related to SMA and 
eWASO, and inversely related to eTST, and eSE%; (c) rMEQ-CA was positively correlated with 
TIB and eTST, and negatively correlated with SMA; and (d) CSF hcrt-1 level was positively 
correlated with eTST, and MSLT-sl, and negatively with eNap and aESS. In the control group, only 
a negative correlation between aESS and TIB reached statistical significance. 
 
DISCUSSION 
 
Our study was the first specifically aimed at analyzing rest-activity rhythm in a sizeable group of 
drug-naïve NT1 children, monitored in real-life setting during the school week. We found that, 
despite a comparable sleep phase, NT1 children showed an altered circadian rest-activity rhythm 
compared to age- and sex- matched healthy children. 
Circadian analyses revealed that the most striking differences between our cohort of NT1 versus 
control children were time-locked to nighttime, when NT1 children presented higher motor activity 
levels maintained throughout the nocturnal period, and to the early afternoon, when NT1 children 
displayed lower motor activity. Conversely,  NT1 and control children showed similar activity 
41 
 
levels during morning and evening hours. To our knowledge, the present report is the first 
investigation on circadian rhythms in pediatric NT1 patients, nonetheless the circadian rhythm 
abnormalities highlighted herewith are remarkably similar to those reported on adult NT1 patients. 
In line with our findings, a recent study compared circadian pattern of melatonin secretion (through 
assay of plasma melatonin concentration) of adult NT1 patients and controls and showed that, 
although average hormone concentrations across the 24-hr did not differ between groups, the 
circadian pattern of melatonin release was altered in NT1, with patients presenting a higher 
proportion of melatonin secreted during daytime and a major peak of secretion in the early 
afternoon between 14:00 and 16:00.
21
 
Further evidences for altered circadian rhythmicity in NT1 is supported  also by cognitive studies: 
Schneider and co-authors compared daytime variations of performances in cognitive task assessing 
alertness and selective attention in four groups of adults with sleep disorders (NT1, 
psychophysiological insomnia, and treated or untreated obstructive sleep apnea syndrome) and 
controls, highlighting a peculiar pattern of daytime fluctuations in NT1 patients, along with the 
lowest mean performance in all cognitive functions.
35
 Performance of NT1 patients was higher in 
the early morning (08:00), thereafter it quickly deteriorates until reaching a nadir in the early 
afternoon (14:00) before rebounding again to levels similar to those of morning session around 
18:00. On the contrary, healthy controls and patients with other sleep disorders showed an initial 
increase in performance and did not presented such major fluctuations during daytime. 
The above findings, along with our observations, suggest that the loss of hypocretinergic neurons 
may lead to an imbalance between the sleep-wake regulating homeostatic and circadian processes,
 
36,37
 weakening the circadian waking drive
 
and its ability to oppose the homeostatic sleep pressure.
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As a result the ultradian and semi-circadian fluctuation of sleep propensity
 
may became 
predominant with untimely intrusion of sleep, regardless of circadian phase.
 39,40
 
Analyzing actigraphic derived nocturnal and diurnal sleep measures we highlighted the good 
discriminant capability of actigraphic monitoring in depicting the marked impairment of both 
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nocturnal sleep and daytime wakefulness in a young cohort of drug-naïve NT1 patients. Indeed, our 
cohort of drug-naïve NT1 children presented numerous sleep episodes and lower motor activity 
counts during daytime, associated with major nocturnal sleep fragmentation and enhanced motor 
activity during nighttime, as previously reported in adult NT1 drug-naïve cases.
14
 This peculiar 
nycthemeral disruption, already detectable by means of actigraphy in NT1 children close to disease 
onset, should be regarded as an intrinsic disease hallmark.  
Although actigraphy recommendations in the diagnostic work-up of NT1 are confined to rule out 
sleep deprivation and circadian rhythm disorders prior to MSLT,
1
 we showed the good discriminant 
capabilities of actigraphic assessment, both in adult and pediatric NT1 cases.
14
 Actigraphy also 
offers the possibility to monitor patients in their own environment allowing us to document long-
lasting diurnal sleep episodes that are often reported in childhood NT1.
41
 The standard diagnostic 
approach, based on the nocturnal polysomnography followed by the MSLT, allows a proper 
neurophysiological diagnosis with high sensitivity and specificity, but does not give insight into this 
very common aspect of NT1 hypersomnolence.
1
 
Finally, we reported that increased BMI, high subjective sleepiness and low CSF hcrt-1 levels were 
associated with the severity of nycthemeral disruption in childhood NT1 pointing to the possibility 
to further objectively stratify disease severity.  
Some limitations of the present study need to be acknowledged. First, although this cohort 
represents the largest actigraphic study on pediatric NT1, the sample is still relatively small and 
prevented us from categorizing children according to pubertal maturation. Second, we did not 
evaluate other markers of the circadian clock (e.g. melatonin or cortisol) besides the rest-activity 
rhythm to test whether the blunted motor activity pattern during daytime was coupled with altered 
endocrine secretions.  
Although actigraphy remains a screening method that cannot substitute the gold standard diagnostic 
protocol for NT1 (namely nocturnal polysomnography followed by MSLT and CSF hcrt-1 
measurement), this monitoring may offer a complementary measure to support the diagnosis of 
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pediatric NT1 especially enhancing the diagnostic probability of questionable cases, to track disease 
course over time, and to tailor supportive strategies. First, we showed that actigraphy can document 
different daytime and nighttime impairments in a more ecological and cost-effective way compared 
to laboratory procedures, and could represent an objective tool to assess disease burden in real-life 
settings. Second, given that behavioral treatment (i.e. regularly scheduled naps) is a major 
management strategy for NT1,
42
 actigraphy can be used to objectively assess, and possibly adjust, 
the napping schedule. Third, different studies have shown the ability of actigraphy in assessing 
wake-promoting drugs and sodium oxybate effects, highlighting that actigraphy could represent a 
very less expensive and ecological approach to assess treatment outcome and prospectively track 
disease course.
16,17
 Fourth, the observation of a discrete circadian profile of blunted motor activity 
in NT1 children provided additional insight into the nature of diurnal variation and suggested that 
the quantitative assessment of motor activity is a promising behavioral biomarker of NT1 in young 
patients. Further studies are needed to test the reliability of actigraphy for wide-scale 
epidemiological studies as a screening tool to steer towards proper diagnosis of NT1 and hopefully 
reduce diagnostic delay and disease burden. 
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Table 1. Demographics, scale scores, neurophysiological data and hypocretin-1 levels of children with  type 1 
narcolepsy and healthy controls.  
Variable Mean ± SD Mean ± SD p
a
 ES 95% CI 
 NT1 (n=22) Controls (n=21)   lower upper 
Demographic and clinical data       
Male/female (10/12) (13/8) 0.28    
Age, years 12.09 ± 2.37 10.95 ±  2.25 0.11  -0.28 2.56 
Age at NT1 onset, years 9.66 ± 2.21      
Diagnostic delay, years 3.09 ±  2.16 
(range 0.2-8) 
     
     
BMI 24.53 ± 6.83 19.83 ± 2.68 <0.0005 0.9 1.48 7.93 
aESS 13.86 ± 3.37 3.14 ± 3.17 <0.0001 3.27 8.7 12.74 
rMEQ-CA 15.32 ± 3.66 15.14 ± 3.07 0.87  -1.91 2.26 
Chronotype (m\i\e) (7:13:2) (2:18:1) 0.14    
MSLT and Hypocretin-1 data       
MSLT-sl, min 4.15 ± 3.02 
(range 1-13*) 
     
SOREMPs, number 4.36 ± 0.85 
(range 2 - 5) 
     
CSF hcrt-1, pg/ml 18.64 ± 28.98 
(n = 17; range 0-109.30) 
     
NT1= type 1 narcolepsy; ES= Cohen's d; CI = confidence interval of difference between means; BMI = body mass 
index; aESS = adapted Epworth sleepiness scale; rMEQ-CA = reduced Morningness-Eveningness questionnaire for 
Children and Adolescent; chronotype: m = morning type, i = intermediate type, e = evening type; MSLT = multiple 
sleep latency test; MLST-sl = mean sleep latency at  MSLT; SOREMPs = sleep-onset REM periods; CSF = 
cerebrospinal fluid; hctr-1 =  hypocretin-1. 
*2 cases with MSLT-sl > 8 min 
a 
p-values derived from Chi-square test or Student's t-test  as appropriate. 
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Table 2. Actigraphic nighttime, daytime and sleep timing measures (Means and SD) of children with  type 1 narcolepsy and healthy controls. 
Variable Mean ± SD Mean ± SD t-test(41) p Cohen's d 95 % CI 
 NT1 (n = 22) Control (n = 21)    lower upper 
Sleep Timing        
BT 22:37 ± 00:51 22:22 ± 00:40 1.07 ns  -0.22 0.72 
GUT 07:06 ± 00:37 07:12 ± 00:24 -0.65 ns  -0.42 0.22 
MS 02:51 ± 00:33 02:47 ± 00:27 0.52 ns  -0.23 0.39 
TIB (min) 510.34 ± 59.12 532.10 ± 35.98 -1.45 ns  -52.08 8.56 
Nighttime period        
eSOL (min) 10.97 ± 3.70 11.31 ± 6.11 -0.22 ns  -3.44 2.75 
eTST (min) 326.84 ± 77.90 479.60 ± 39.53 -8.05 <0.0001 -2.46 -191.09 -114.43 
eSE%  63.89 ± 12.95 90.19 ± 5.20 -8.66 <0.0001 -2.64 -32.44 -20.17 
eWASO (min) 167.42 ± 65.34 39.05 ± 27.79 8.31 <0.0001 2.54 97.17 159.56 
eAwk (n°) 32.10 ± 7.60 15.10 ± 6.04 8.1 <0.0001 2.47 12.76 21.24 
eAwk>5 (n°) 10.09 ± 2.63 3.07 ± 2.64 8.74 <0.0001 2.66 5.4 8.64 
SMA (counts) 30.54 ± 12.37 11.64 ± 4.18 6.64 <0.0001 2.03 13.15 24.64 
Daytime period        
DMA (counts) 197.66 ± 23.20 219.29 ± 17.69 -3.42 <0.001 -1.05 -34.37 -8.87 
eDTST (min) 66.93 ± 26.47 5.33 ± 7.79 10.24 <0.0001 3.13 49.45 73.74 
eNap (n°) 4.81 ± 1.76 0.29 ± 0.46 11.41 <0.0001 3.48 3.72 5.32 
eNapD (min) 38.53 ± 15.21 4.48 ± 7.36 9.27 <0.0001 2.83 26.64 41.47 
BT, clock time (in hours and minutes) when subject goes to bed and turns off the light;  GUT, clock time  (in hours and minutes) when subject 
gets out of bed in the morning;  MS, clock time (in hours and minutes) that split in half the TIB; TIB, time in bed (min); eSOL, estimated sleep 
onset latency (min); eTST, estimated total sleep time (min); eSE%, estimated sleep efficiency (%); eWASO estimated wake after sleep onset 
(min); eAwk, number of estimated awakenings; eAwk >5, number of estimated awakenings longer than 5 consecutive minutes; SMA, mean 
activity counts during TIB; DMA, mean activity counts during daytime; eDTST estimated total sleep time during daytime (min); eNap, number 
of daytime estimated sleep episodes longer than 5 consecutive minutes; eNapD, mean duration of longest estimated sleep episode (min)  
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Table 3  Pearson’s correlations between clinical, neurophysiological data, scale 
scores and actigraphic-derived measures. 
  
NT1 (n = 22) Controls (n = 21) 
BMI aESS rMEQ-CA 
hcrt-1 
(n=17) 
BMI aESS rMEQ-CA 
TIB -0.50
*
 -0.20 0.43
*
 0.09 0.16 -0.51
*
 0.43 
eSOL 0.33 0.18 -0.22 -0.01 -0.16 -0.07 0.24 
eTST -0.67
**
 -0.59
**
 0.56
**
 0.49
*
 0.12 -0.42 0.23 
eSE% -0.57
**
 -0.60
**
 0.41 0.47 0 -0.04 -0.13 
eWASO 0.32 0.50
*
 -0.27 -0.42 0.06 -0.03 0.15 
eAwk -0.53
*
 -0.32 0.23 -0.10 -0.17 0.09 0.10 
eAwk>5 0.07 0.36 -0.14 -0.40 0.22 -0.21 0.25 
SMA 0.63
**
 0.59
**
 -0.51
*
 -0.28 0.12 0.03 0.16 
DMA -0.11 0.02 0.08 0.29 0.11 0.17 -0.07 
eDTST -0.01 -0.03 -0.22 -0.31 0.25 -0.29 0.29 
eNap -0.04 -0.05 -0.06 -0.58
*
 -0.13 -0.20 -0.07 
eNapD -0.28 -0.14 -0.25 -0.31 0.24 -0.29 0.21 
MSLT-sl -0.13 -0.18 0.24 0.61
**
    
SOREMPs 0.06 -0.07 -0.10 -0.21    
BMI – 0.58
**
 -0.29 -0.30 – 0.03 -0.09 
aESS  – -0.24 -0.59
*
  – -0.37 
rMEQ-CA   – -0.40   – 
NT1= type 1 narcolepsy; aESS = adapted Epworth sleepiness scale; rMEQ-CA = 
reduced Morningness-Eveningness questionnaire for Children and Adolescent; hcrt-
1 = hypocretin-1; TIB = time in bed; eSOL = sleep onset latency; eTST = total 
sleep time; eSE% = sleep efficiency; eWASO = wake after sleep onset; eAwk = 
number of awakenings; eAwk>5 = number of awakenings longer than 5 minutes; 
SMA = mean motor activity counts during nighttime; DMA = mean motor activity 
counts during daytime; eDTST = daytime total sleep time; eNap = number of 
diurnal sleep episodes; eNapD = mean duration of longest diurnal sleep episode; 
MSLT-sl = mean sleep latency at multiple sleep latency test; SOREMPs = sleep 
onset REM periods. 
*
p<0.05;
**
p<0.01 
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Legend 
 
Figure 1. Functional linear modeling for NT1 and controls. Plot (a) shows estimated activity 
patterns for the two groups. Plot (b) shows F-test result, the red curve represents the observed 
statistic, the blue dashed and dotted lines correspond to a global and point-wise test of significance 
at α = 0.05. 
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Chapter 4 
Functioning of attentional networks and ADHD 
symptoms in narcolepsy with or without 
hypocretin deficiency. 
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ABSTRACT 
 
Objectives: Attentional impairments are a common symptom in type 1 narcolepsy (NT1) that 
adversely interferes with several aspects of everyday life. Nevertheless, only few study attempted to 
characterize attentional deficits in NT1 and results are still elusive. This study examined whether 
NT1 patients would exhibit deficits in alerting, orienting, and executive control of attention relative 
to patients with type 2 narcolepsy (NT2) and healthy controls. 
Methods: Twenty-one NT1 patients compared to Fifteen NT2 patients and twenty-two healthy 
controls matched for age and gender. All participants completed the attentional network test (ANT) 
and responded to questionnaires regarding frequency of ADHD symptoms, sleepiness, anxiety and 
depression. 
Results: NT1 display a deficit in alerting network relative to NT2 and controls, while orienting and 
executive network resulted preserved. Moreover, alerting network efficiency significantly correlate  
with levels subjective sleepiness in NT1 patients. NT1 and NT2 patients reported an increased 
frequency of ADHD symptoms relative to controls, NT1 patients also present higher intensity of 
depressive symptom. The severity of ADHD symptoms significantly correlated with subjective 
sleepiness and depression.  
Conclusions: This study show that NT1 patients have a selective deficit in alerting network 
functioning, and that NT1 and NT2 patients report an increased frequency of ADHD symptoms. 
Take account of attentional deficits and ADHD comorbidity in clinical assessment of narcolepsy 
may be of great beneficial for patients. 
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INTRODUCTION 
 
Type 1 Narcolepsy (NT1) is a life-long neurological disorder characterized by chronic 
hypersomnolence with multiple sleep attacks, often characterized by direct transitions into rapid eye 
movement (REM) sleep (sleep-onset REM periods, SOREMPs), untimely manifestations of 
dissociated REM sleep, the most specific of which is cataplexy (sudden loss of muscle tone 
triggered by emotions),
1
 and nocturnal sleep disruption.
2,3 
It is now recognized that NT1 is caused by a loss of hypothalamic neurons that produces 
hypocretin, a wakefulness-associated neuropeptide.
4
 NT1 patients have reduced or absent levels of 
hypocretin-1 (hcrt-1) in their cerebrospinal fluid (CSF), accordingly the disease is further classified 
into NT1 (with hypocretin-1 deficiency and cataplexy) and Narcolepsy Type 2 (NT2), where 
cataplexy is absent and hypocretin levels are usually in the normal range.
1 
Although initially described as specifically involved in regulating arousal, wakefulness, and feeding 
behavior, is now clear that hypocretin influence and participate in a wide range of behavioral and 
physiological processes.
5,6
 Hypocretinergic neurons have a key role in facilitating cognitive 
processes, particularly in regulating attention and arousal, via strong interaction with 
monoaminergic and cholinergic systems in the basal forebrain regions.
7
 
These findings have led several investigators to question whether an underlying cognitive 
impairment might accompany the classical symptoms of NT1. A considerable number of clinical 
reports support this hypothesis: concentration and memory problems are reported by a significant 
portion of NT1 patients,
8
 and represent a major concern in this clinical population.
9 
Nevertheless, has been unexpectedly difficult to document and characterize such impairments in 
experimental studies.
10 
Memory assessments with standardized neuropsychological batteries 
showed intact performance of NT1 patients in short and long-term memory task.
11 
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Several reports have pointed to deficit in attentional functioning. In the majority of studies NT1 
patients present markedly slower and more variable reaction times (RTs) relative to controls, while 
performance accuracy resulted mainly preserved.
12-14 
Consistent empirical evidences showed that NT1 patients display impairments in tonic alertness and 
sustained attention, observable during long and monotonous tasks.
15-17 
Evidences of impairments in a specific attentional subcomponent are less consistent: in a extensive 
investigation on attentional domain in NT1, Rieger and co-authors reported specific deficits in 
divided and flexible attention, with preserved phasic alertness and focused attention.
12
 Similarly, 
Naumann and co-authors reported intact tonic alertness and arousability, while deficits emerged in 
more complex tasks that requires a higher cognitive load.
13
  
Despite the available evidence seems to point at a selective deficit in attentional subcomponents 
rather than to a global impairment, the extremely limited number of studies and the discrepancy 
between results does not allow to state meaningful conclusions. One of the major difficulties in 
comparing studies' outcomes is due the great heterogeneity of neuropsychological tests chosen for 
evaluate the different aspects of attentional process. A possible approach to obviate this issue is 
select cognitive tasks designed according to proposed neurocognitive models of attentional 
functioning. According to an influential neurocognitive model, attention is a complex and 
multidimensional system defined as the activity of a network of separate anatomical areas, each 
dedicated to a discrete aspect of attentional processes.
18
 Three separate subsystems were postulated: 
the alerting, orienting, and executive control networks.
19
  
 
Alerting network encompasses the ability to achieve and maintain a state of high sensitivity to 
incoming stimuli; orienting network encompasses the ability to selectively drive attention to task-
informative sensory stimuli; the executive control network encompasses the ability to focus 
attention on task-relevant stimuli and ignore distracting information. Neuroimaging studies have 
demonstrated that each network is associated with the activation of specific, although partially 
overlapping, set of brain areas.
20,21
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Within this theoretical framework, the attention network test (ANT) was designed in order to assess 
the functioning of each network during a single testing session.
22
  
The ANT has quickly become a popular tool in neurocognitive research, and has been extensively 
applied to characterize attentional impairments in several clinical populations, including 
patients with stroke, schizophrenia, and attention-deficit/hyperactivity disorder (ADHD).
23-,25
  
However, to the best of our knowledge, it has never been used in patients with central disorders of 
hypersomnolence. 
The main aim of present study is to investigate whether specific changes in attentional networks 
functioning could be observed in narcoleptic patients with hypocretin deficiency (NT1) compared to 
narcoleptic patients without hypocretin deficiency (NT2) and healthy controls matched for age and 
gender. A secondary aim of the study is to evaluate frequency and severity of ADHD and 
obsessive-compulsive disorder (OCD) symptoms in adult NT1 and NT2 patients versus healthy 
controls. 
Recently, two studies showed that NT1 children present an increased frequency of ADHD 
symptoms compared to controls;
26,27
 however, to the best of our knowledge, no attempt was 
conducted to determine whether higher prevalence of ADHD symptoms persist in adult NT1 
patients. Given that deficit in alertness and disrupted sleep are considered to be involved in the 
pathogenesis of ADHD, we expect to find higher prevalence of ADHD symptoms in adult NT1 
cases.
28
  On the other hand, evidences of an association between NT1 and OCD are limited to few 
case reports,
29 
nonetheless a shared trigger for an autoimmune process (i.e. streptococcal 
infections), is supposed to be involved in the pathogenesis of both diseases.
30
   
Finally, we are interested in exploring the relationship between clinical, biochemical, self-report 
measures and performances at attentional task. 
 
METHOD 
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Subjects 
 
Subjects were consecutive adult patients evaluated for complaints of chronic hypersomnolence at 
the outpatient clinic for Narcolepsy of the Department of Biomedical and Neuromotor Sciences, 
University of Bologna, and who received a final diagnosis of narcolepsy (either type 1 and type 2) 
according to current International Classification of Sleep Disorders 3rd edition (ICSD-3) criteria.
1
 
All patients underwent a standardized diagnostic protocol encompassing clinical evaluation with 
assessment of subjective sleepiness with the Epworth Sleepiness Scale (ESS),
31
 at-home actigraphic 
monitoring and cerebral magnetic resonance imaging (to rule out secondary cases), and 
hospitalization with 48-hr continuous polysomnographic recording, Multiple Sleep Latency Test 
(MSLT), cataplexy video-documentation, human leukocyte antigen (HLA) typing and, whenever 
possible, lumbar puncture for CSF hypocretin-1 (Hcrt-1) assay. 
The final study sample included 36 patients, consisting of twenty-one NT1 patients (9 males, mean 
age 36.19 ± 11.94 years) and fifteen NT2 patients (6 males, mean age 35.47 ± 13.05 years). 
All NT1 patients fulfilled current ICSD-3 clinical criteria for type 1 narcolepsy presenting severe 
daytime sleepiness (mean ESS = 15.90 ± 5.30) and clear-cut cataplexy (n = 21/21).
1
 
Nineteen out of 21 cases had mean sleep latency < 8 min (mean 4.41 ± 4.80) with at least two 
SOREMPs (mean 3.71 ± 1.49) at the MSLT. Nineteen patients (including the 2 cases with MSLT 
sleep latency > 8 min.) underwent lumbar puncture and all had low (≤ 110 pg/ml) or undetectable 
CSF Hcrt-1 levels; all patients were drug-naïve at time of evaluation. 
NT2 diagnosis was made according to current ICSD-3 criteria with all patients presenting persistent 
daytime sleepiness (mean ESS= 15.53 ± 5.45), absence of cataplexy, and mean sleep latency < 8 
min (mean 7.31 ± 2.98) with at least two SOREMP (mean 1.4 ± 1.72) at MSLT or nocturnal 
polysomnography.
1
 Hcrt-1 concentration was higher than >110 pg/ml in all patients tested (n = 
11/14),
1
 thirteen patients were drug-naïve, two patients had discontinued treatment with 
psychostimulants three week prior to hospitalization. 
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Twenty-two age- and sex- matched controls (11 males, mean age 34.95 ± 11.52 years) were 
recruited from the local community. Participants were screened to rule out sleep or medical 
disorders; more in detail they filled in the ESS, the Beck Depression Inventory (BDI),
32  
the State-
Trait Anxiety Inventory (STAI-Y),
33
 and underwent to seven day of  actigraphic monitoring. 
Subjects with regular sleep schedule and without complaints of daytime sleepiness (mean ESS = 
7.05 ± 3.34), depression (BDI < 21), or anxiety (STAI < 40) were included. The study was 
approved by the internal review board and all participants provided written informed consent. 
 
Attention Network Test 
 
The original version of the ANT, was used in this study.
22 
The ANT is a combination of the cued 
reaction time
34 
and the flanker task,
35 
by manipulating stimulus property the task assess the 
efficiency of each network measuring subjects’ RTs. The task was presented via E-Prime 2.0 
software (Psychology Software Tools, Inc., Sharpsburg, PA), stimuli were displayed on a 15-in 
monitor and responses collected via "Q" and " P" keys on a standard keyboard. Participants were 
seated approximately at 60 cm from the monitor, in a sound-attenuated room with controlled 
luminance levels, and were instructed to focus on a fixation cross that appears in the center of the 
monitor and remains on screen until the end of the test. 
The sequence of events of the task is reported in Figure 1. In each trial, after a variable fixation 
period (range 400–1600 ms), a warning cue lasting 100 ms is presented (four cue conditions: no-
cue, double-cue, spatial-cue, or center-cue), subsequent to a constant fixation period (400 ms) the 
target and flankers were presented  until the participant responds or the maximum duration interval 
(1700 ms) is expired. 
The target, a central arrow in a row of five arrows, can appear 1.06° above or below the fixation 
point and is flanked by arrows (2 on each side) pointing in the same direction (congruent condition), 
or in the opposite direction (incongruent condition), or is not flanked by additional stimuli (neutral 
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condition). Participant have to indicate, as quickly and accurately possible, in which direction the 
central arrow is pointing. 
An index for the alerting network is derived subtracting mean RTs of trials with double-cue from 
mean RTs of trials without warning cue (RTno cue –RTdouble cue); both no-cue and double-cue 
conditions do not provide information on the spatial location of incoming target, but the double-cue 
alerts participant of the imminent appearance of the target. 
An index for the orienting network is computed subtracting mean RTs of trials with spatial-cue 
from mean RTs of trials with center-cue (RTcenter cue − RTspatial cue); both cues warn subject of the 
imminent appearance of the target, but only spatial-cue provides meaningful information able to 
enhance the orientation of attention toward the appropriate location. 
Finally, an index for the executive control network is calculated by subtracting mean RTs of trials 
with congruent flanker from mean RTs of trials with incongruent flanker (RTincongruent − RTcongruent); 
the two conditions differ in the type of information provided by flankers that facilitate the 
discrimination of stimuli when congruent, while distract subject when incongruent. 
 
Self-Report Measures 
 
Upon completing the ANT, participants completed questionnaire assessing presence and severity of 
symptoms of ADHD and OCD. 
The Adult ADHD Self-Report Scale Symptom Checklist (ASRS) is a questionnaire designed to 
assess the severity of ADHD symptoms in adulthood, according to DSM-IV criteria.
36
 
The ASRS  encloses two subscales, for a total of 18 items: one subscale assess inattentive 
symptoms (i.e. difficulties to pay attention, excessive distractibility, difficulties organizing tasks)  
the second assess hyperactive/impulsive symptoms (i.e. fidget or restless behavior, excessive 
activity, difficulty in remaining seated).  
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Participants were asked to rate each item on a 5-point Likert scale (ranging from 0 = never to 4 = 
very often): the sum of nine item assessing inattentive symptoms determine the ASRS inattentive 
score (ASRSIn), the sum of nine item assessing hyperactive/impulsive symptoms determine the 
ASRS hyperactive score (ASRSHy), a score computed on six items (ASRS Screener, ASRSScr) 
provides clinical cut-off value.
37
 
The reduced version of the Obsessive Compulsive Inventory (OCIr)  is a 18-item questionnaire 
assessing the degree of distress associated with obsessions and compulsions.  
Participants were asked to express, on a 5 point Likert scale (ranging from 0 = not at all to 4 = 
extremely) the distress associated with the proposed statements.
38
 
Beck Depression Inventory (BDI) and State-Trait Anxiety Inventory (STAI) were used to assess 
participants’ levels of depression and anxiety, respectively.32,33 Circadian typology was evaluated 
with the reduced version of morningness/eveningness questionnaire (rMEQ).
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Procedure 
 
NT1 and NT2 patients were evaluated during the hospitalization finalized to the diagnostic protocol. 
The experimental evaluation took place over two days: in the first day participants were instructed 
on study protocol and provided written informed consent, then practiced with a full version of the 
ANT, in order to minimize possible learning effect;
40
 in the second day, after an overnight 
polysomnography, the ANT was administered at a fixed hour (after the mid-afternoon peak of 
sleepiness,
41 
around 17:30), given that performances can vary as a function of time-of-day.
42
 
The experimenter was present at the beginning of the testing session to start the task and answer 
participants' questions, the instructions (verbal and written) describes the procedures and emphasize 
the importance of a quick and accurate response. 
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Participants completed 1 practice block of 26 trials with feedback, followed by three experimental 
block without feedback consisting of 96 trials each (4 cue conditions × 2 target locations × 2 target 
directions × 3 flanker conditions × 2 repetitions); trials were presented in random order. 
Healthy controls underwent the same experimental protocol; however, in order to ensure adequate 
sleep duration (at least 6 hr) and regular sleep schedule prior to testing session, they were monitored 
throughout 7 days by means of actigraphy. 
Controls were evaluated at the Laboratory of Applied Chronopsychology, Department of 
Psychology, University of Bologna, at the same hour of day (i.e. 17:30) of the clinical groups. 
 
Statistical Analyses 
 
Data were explored with descriptive statistics (mean ± SD). Group differences in demographical 
data, BMI and questionnaire scores were analyzed with chi-square test, Mann-Whitney U test, and 
one-way analysis of variance (ANOVA). 
For the attentional task we computed the mean overall RTs, accuracy rate, and the efficiency of the 
three attentional networks; moreover we also computed mean RTs for each participant in the 12 
different test conditions (4 cue types X 3 flanker types). Trials in which participants made errors or 
trials with RTs ± 3 SD from the mean were excluded from analysis. RTs are generally slower in 
patients, consequently we calculated a proportional transformation (Pro) on network score to 
examine specific effects in a manner that is independent from global slowing; proportional scores 
were computed dividing networks score by a measure of information processing speed (RTAll = 
mean RTs for all 12 warning Cue X flanker conditions).
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For the ANT networks score, we first conducted a correlation analyses to assess the independence 
of the three attentional component. Subsequently, we carried out a MANOVA considering the 
following variables: overall RTs, accuracy, Alerting, Orienting and Executive network score and 
the proportional scores of these latter. 
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In the event of a significant omnibus effect at MANOVA, univariate effects for dependent variables 
were explored, where these were significant Bonferroni post-hoc were used to determine the nature 
of the between groups effects, partial-Eta² (np2) was computed as a measure of effect size. 
Furthermore for each attentional network, we carried a repeated measures ANOVA with group as 
between subject factor and the type of cue or flanker that defined the specific network as within-
subject factor (2 levels) (i.e., no-cue and double-cue for Alerting, central-cue and spatial-cue for 
Orienting, incongruent and congruent flanker for Executive). 
Finally, the relationship between clinical, self-reported measures and performance at cognitive task 
was explored, separately for each group, with correlation coefficient analysis. Statistical analyses 
were conducted using SPSS 19.0 (SPSS, Inc. Chicago, Ill). Results with p values <0.05 were 
considered statistically significant.  
 
RESULTS 
 
Demographic, clinical, neurophysiological characteristics and questionnaires scores are reported in 
Table 1, together with ANOVA and post-hoc results. Chi-square and one-way ANOVA analyses 
showed no group differences in either gender and age, as well as in circadian typology distribution. 
NT1 patients display higher BMI than NT2 and controls, without any significant difference between 
these latter. One-way ANOVA showed a main group effect for ASRSIn and ESS, with both NT1 
and NT2 patients reporting higher frequency of ADHD inattentive symptoms and higher level of 
subjective sleepiness than controls. For the NT1 group, difference also emerged in the ASRSHy and 
BDI score, with patients reporting higher frequency of ADHD hyperactive symptoms and higher 
intensity of depressive symptoms than controls, without any other between group difference. No 
differences were observed in state and trait anxiety level as well as in OCIr score. 
The first set of correlations, aimed to explore the independence of attentional networks score, 
highlighted very feeble associations between alerting and orienting, alerting and executive, and 
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orienting and executive score (r = 0.14, r = 0.01, and r = -0.12  respectively, all p ≥ 0.38). Mean and 
standard deviation of ANT network scores, proportional score, overall RTs, and accuracy data for 
the three groups are shown in Table 2, together with significance values at ANOVA, partial-Eta², 
and Post-Hoc results.  
NT1 and NT2 patients display slower overall RTs than the controls, without differ in performance 
accuracy. Analyses shows that NT1 patients present higher alerting score than NT2 and controls, 
this trend in difference reach statistical significance even when network score is computed in a 
manner that is independent from a global slowing of  processing speed. Contrarily, no differences 
emerged between patients and controls on orienting and executive networks score, nor in the 
proportional scores of these latter. Box plot for attentional network scores of the three groups are 
reported in Figure 2.  
Results of the three repeated measures ANOVA performed on mean RTs for the clue and flanker 
conditions that define the attentional processes assessed by the ANT are reported in Figure 3. 
The alerting effect was explored with a 3 (Group: NT1, NT2, controls) X 2 
(Cue condition: no-cue, double-cue) repeated-measure ANOVA; analysis showed a main effect of 
Group (F2,55 = 8.935; p = 0.0004; np
2
 = 0.245 ) with both NT1 and NT2 patients responded 
more slowly than controls, and a main effect of Cue (F1,55 = 143.626; p < 0.0001; np
2 
= 0.723) with 
faster RTs in the double-cue than in the no-cue condition. 
Most important, a two-way interaction "Cue by Group" resulted statistically significant (F2,55 = 
7.394; p < 0.001; np
2
 = 0.212); this interaction was due to larger differences  between RTs in no-cue 
(666.86 ± 21.93 ms) and double-cue (601.57 ± 21.05 ms) condition of NT1 patients relative to NT2 
(no-cue 636.73 ± 25.95 ms, double clue 602.73 ± 24.91 ms) and controls (no-cue 535.58 ± 21.43 
ms, double clue 498.96 ± 20.57 ms). 
The orienting effect was explored with a 3 (Group: NT1, NT2, controls) X 2 (Cue condition: center-
cue, spatial-cue) repeated-measure ANOVA, results show a main effect of Group (F2,55 = 9.727; p = 
0.0002; np
2
 = 0.261) with both clinical groups were more slower than controls, and a main effect of 
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Cue (F1,55 = 114.074; p < 0.0001; np
2
 = 0.675) with faster RTs in the spatial-cue compared to center-
cue condition. The interaction between factors did not reach statistical significance (F2,55 = 0.971; p 
= 0.385; np
2
 = 0.034). 
The flanker effect was explored with carrying a 3 (Group: NT1, NT2, controls) X  2 (Flanker type: 
congruent, incongruent) repeated-measure ANOVA; results highlighted a main effect of Group 
(F2,55 = 9.232; p = 0.0003; np
2
 = 0.251), and a main affect of Flanker (F1,55 = 127.648; p < 0.0001; 
np
2
 = 0.699) with faster RTs in the congruent-flanker condition compared to incongruent-flanker 
condition. The interaction between factors (F2,55 = 0.767; p = 0.469; np
2
 = 0.027) did not reach 
statistical significance. 
Pearson’s correlation analyses are reported, separately for each group, in Table 3. In the NT1 group 
BDI was positively correlated with ESS, ASRSIn and ASRSHy,  the ESS was directly related to 
ASRSIn and display a negative relationship with alerting network efficiency (Figure 4 ). In the NT2 
group, only a positive correlation between ASRSIn and ASRSHy reached statistical significance, no 
significant correlation were observed for the control group. 
 
DISCUSSION 
 
The present study is the first aimed at  investigating the functioning of the three attentional 
networks postulates by Posner and co-authors, in a sizable cohort of drug-naive patients with NT1 
and NT2 versus healthy controls.
19
 In accordance with previous studies , NT1 and NT2 patients 
resulted markedly more slow than controls, without differ in performance accuracy.
12-14
 The most 
striking finding is a specific alteration in the alerting network of NT1, while no difference emerged 
respect to control regarding the orienting and executive control network. The aberrant functioning 
of alerting network showed in NT1 patients, result statistically significant even when network score 
is computed with a proportional score transformation, that is a robust way to unveil group 
difference in attentional processes independently from global slowing. The larger alerting effect 
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displayed by NT1 patients, relative to NT2 patients and controls, may indicate either an inability to 
benefit from warning-cue to speed-up RTs, or a deficit in maintaining adequate alertness in absence 
of warning-cues. 
Bearing in mind that ANT network scores are computed with a subtractive logic, larger alerting 
scores do not necessarily indicate less efficient performance, but may reflect that one group need to 
compensate the difficulties aroused by the task increasing the effort.
44
  In this scenario, for a proper 
interpretation of ANT outcome, is crucial to consider the distinction between tonic and phasic 
alertness processes: in trials without warning-cue participants must rely on their own internal 
arousal system, hence RTs in no-cue trials reflect the more tonic aspects of alertness; conversely 
when a warning-cue precede the event of interest participants may use the information provided to 
enhance RTs, hence RTs in the double-cue trials reflect the phasic component of alertness (i.e. 
arousability). 
Considering that in trials with double-cue NT1 and NT2 display similar mean RTs (601.57 ± 21.05 
ms vs 602.73 ± 24.91 ms) compared to RTs in trials without warning cue (666.86 ± 21.93 ms vs  
636.73 ± 25.95 ms), we can conclude that in NT1 patients the tonic component of alertness is 
markedly impaired while the ability to use warning-cue to improve RTs is essentially preserved. 
This profile of impaired tonic alertness with preserved arousability presented by NT1 patients is 
consistent with previous studies, that however assessed attentional functioning by means of separate 
and independent cognitive tasks, and highlights the sensitivity of the ANT in rendering this peculiar 
attentional functioning within a single, short, testing session.
12,13
   
In contrast with previous report,
14, 17,45
 no evidence of impaired executive control of attention was 
observed in our sample of narcoleptic; we interpreted this ambiguous result as a clue that the ANT 
is not sensitive enough for detect an impairment in executive functions for this clinical population. 
The peculiar impairment of alerting processes of NT1 patients, might offer new insight on the 
nature of cognitive deficit affecting this clinical population, and on the impact of the latter on 
complains of memory deterioration, often reported by NT1 patients.   
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Attention and memory are closely related, in order to memorize something one must attend it: in 
NT1 the unstable tonic component of alerting process made necessary monitoring and 
compensation strategies, this can lead to a reduction of the available resources and affect mnemonic 
processes. 
Analyzing self-report measures we showed that in patients with NT1 and NT2, ADHD symptoms 
were significantly higher relative to controls. 
Both NT1 and NT2 patients show an increased frequency of ADHD inattentive symptoms, mirrored 
by higher mean ASRSIn score; NT1 patients presented also an increased frequency of ADHD 
hyperactive/impulsive symptoms, as well as higher depressive complaints compared to controls. 
In contrast with previous reports, narcoleptic patients did not show increased anxiety levels. 
Classifying ASRSScr score into four-stratum (0–24 scoring approach) as proposed by Kessler an co-
authors,
37
 including low negative (range 0-9), high negative (range 10-13), low positive (range 14-
17) and high positive (range 18-24), 90.9 % of healthy controls reported scores in the lower stratum 
(0-9) and two subjects (9.1%) reported score in the 10-13 interval; on the contrary only the 44% of 
narcoleptic patients (47.6 % of NT1 and 40 % of NT2, respectively) display score in the first 
stratum. 
To the best of our knowledge, this is the first study that explored the frequency of ADHD 
symptoms in adult narcoleptic patients; nevertheless, our results are in line with previous 
investigations that reported an increased ADHD symptomatology in NT1 children,
26,27
and highlight 
that a higher ADHD symptomatology may persist in a significant portion of adult NT1 cases. 
Finally, correlation analysis disclosed that within NT1 patients, higher rating of ADHD symptoms 
(ASRSIn and ASRSHy) is significantly associated with BDI and ESS score, while no significant 
correlation emerged in NT2 patients and healthy controls. Intriguingly, in NT1 a significant 
association emerged between ESS and Alerting network score, while no association was observed 
between subjective measures and performance at cognitive task in NT2 and controls. 
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A recent study showed that, apart from the classical symptoms, the majority of NT1 patients also 
suffer from severe fatigue, defined as a subjective experience of mental and/or physical exhaustion 
that does not disappear after a period of sleep.
46 
Although excessive daytime sleepiness and fatigue 
are distinct symptoms they clearly show overlapping feature, as reflected by the moderate (r = 0.27) 
to  high (r = 0.71) correlation between measures reported in different studies.
46,47
,  
Accordingly, we can speculate that the severe fatigue reported by NT1 patients, may be related to 
the compensatory strategies made necessary by the impaired Alerting network.  
Two possible limitations of the present study need to be acknowledged. First, the sample size, 
especially for the NT2 group, is relatively low this might reduce the generalizability of results.  
Second, the flanker task consider as a proxy of executive functions the ability to resolve conflicts in 
the processing of competing stimuli. Although the latter is a key aspect of executive functions, this 
cognitive domain encompass a wide range of distinct processes, including inhibition, set-shifting, 
multitasking, planning and working memory; it is therefore possible that there are more group 
differences in the executive functions that the ANT can assess.  
In conclusion our study showed that despite an overall slowing observable in both NT1 and NT1, a 
specific deficit in alerting network is present in NT1, nonetheless this impairment does not affect 
the whole attentional domain, since no evidences of impairment in the orienting and executive 
networks were observed.  
Future investigations are required to explore the association between activation of brain areas and 
performances at the ANT in NT1. 
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Table 1  Demographic, clinical, neurophysiological characteristics and questionnaire score of patients with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2) and healthy 
controls. 
 
NT1 (n=21) NT2 (n=15) CC (n=22) 
F(2,55) p 
NT1vs CC NT1vs NT2 NT2 vs CC 
Mean±SD Range Mean±SD Range Mean±SD Range post-hoc post-hoc post-hoc 
Gender (M:F) 9:12 6:9 11:11 0.41 
a
 ns 
   Age (years) 36.19 ± 11.94 18-66 35.47±13.05 18-67 34.95±11.52 21-58 0.06 b ns 
   MSLT-sl 4.41 ± 4.80 0.36-20 7.31 ± 2.98 3.20-14.36 
  
57 
c
 0.001 
   SOREMPs 3.71 ± 1.49 0-5 1.4 ± 1.72 0-5 
  
55 
c
 0.001 
   CSF Hctr-1 24.48 ± 35.79 0-109.10 334.80 ± 99.41 132-513 
  
6.93 
d
 0.0001 
   HLA DQB1*0602 18/19 6/12 
 
8.42 
a
 0.005 
   Cronotype m/i/e 3/13/5 4/10/1 1/18/3 5.56 
a
 ns 
   BMI 30.41 ± 6.28 17.58-40.40 25.38±2.86 21.77-32.87 21.88±3.13 17.40-26.38 19.48 b 0.0001 0.0001 0.005 ns 
ESS 15.90±5.30 6-24 15.53±5.45 4-24 7.05±3.34 0-13 22.76 
b
 0.0001 0.0001 ns 0.0001 
BDI 16.86±13.13 0-55 16.27±11.98 3-37 8.14±5.60 1-21 4.32 
b
 0.05 0.05 ns ns 
STAI-S 46.33±14.01 25-74 44.20±11.92 25-64 38.91±9.55 24-57 1.84 
b
 ns 
   STAI-T 47.81±14.37 24-80 47.47±14.23 25-68 40.27±9.63 20-57 2.13 
b
 ns 
   OCIr 18.66±13.25 0-48 15.33±10.33 1-42 11.32±8.36 1-35 1.85 
b
 ns 
   ASRSIn 17.61±6.68 5-36 18.47±9.74 0-36 10.64±4.07 1-19 8.06 
b
 0.001 0.005 ns 0.005 
ASRSHy 14.80±5.51 3-28 13.80±5.21 7-27 10.77±5.02 2-22 3.32
 b
 0.05 0.05 ns ns 
MSLT-sl = mean sleep latency at multiple sleep latency test; SOREMPs = sleep-onset REM periods; CSF Hctr-1 = cerebrospinal fluid hypocretin-1; Chronotype: m = morning 
type, i = intermediate type, e = evening type; BMI = body mass index;  ESS = Epworth Sleepiness Scale; BDI = Beck Depression Inventory; STAI = State Trait Anxiety Inventory 
(S = State, T = Trait); OCIr = reduced obsessive-compulsive inventory; ASRS = adult ADHD self-report scale symptom checklist (In = Inattentive, Hy = Hyperactive).  
a
 Chi-square test 
b One-way ANOVA 
c 
Mann-Whitney U test 
d 
Independent sample T-test 
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Table 2 Mean, standard deviation (SD), univariate and post-hoc results of attentional network test measures and proportional score (Pro) of 
Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2) patients and healthy controls. 
 
NT1 
(n = 21) 
NT2 
(n =15) 
CC 
(n = 22) 
Unviariate 
Results 
 
 
NT1 vs CC 
Bonferroni 
Post-Hoc 
NT1 vs NT2 
Bonferroni 
Post-Hoc 
NT2 vs CC 
Bonferroni 
Post-Hoc 
 
Mean SD Mean SD Mean SD F(2,55) p np
2
 
Alerting 65.30 6.19 34.00 7.33 36.62 6.05 7.40 0.001 .212 0.005 0.006 
 
Alerting(Pro) 0.11 0.01 0.06 0.01 0.07 0.01 5.35 0.008 .163 0.037 0.013 
 
Orienting 39.93 5.88 31.57 6.96 44.17 5.74 0.98 ns 
    
Orienting(Pro) 0.06 0.01 0.05 0.01 0.09 0.01 2.76 ns 
    
Executive 42.28 7.18 52.19 8.49 54.07 7.01 0.77 ns 
    
Executive(Pro) 0.07 0.01 0.08 0.01 0.11 0.01 2.31 ns 
    
Overall RTs 621.08 21.15 605.09 25.03 501.60 20.67 2.68 0.0001 .254 0.001 
 
0.007 
Accuracy(%) 97.56 0.66 96.52 0.78 98.82 0.64 9.37 ns 
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Table 3 Pearson’s correlations between attentional network score and self-report measures of depression, sleepiness, inattentive and hyperactive 
complains. 
 
NT1 (n = 21) NT2 (n = 15) CC (n = 22) 
 
ESS BDI ASRSIn ASRSHy ESS BDI ASRSIn ASRSHy ESS BDI ASRSIn ASRSHy 
Alerting -0.56
*
 -0.32 -0.16 0.12 0.32 -0.41 -0.28 -0.05 0.01 0.06 0.15 0.11 
Orienting 0.14 0.06 0.04 -0.24 0.03 -0.10 -0.29 -0.23 0.05 -0.26 -0.39 -0.18 
Executive -0.03 0.40 -0.04 0.33 0.42 -0.15 -0.26 -0.24 0.05 -0.20 -0.10 0.10 
ESS - 0.55
**
 0.47
*
 0.17 - -0.42 -0.33 -0.09 - -0.01 -0.07 -0.35 
BDI 
 
- 0.67
**
 0.53
*
 
 
- 0.30 0.38 
 
- 0.39 0.27 
ASRSIn   
- 0.46
*
 
  
- 0.77
**
 
  
- 0.26 
ASRSHy    
- 
   
- 
   
- 
ESS = Epworth Sleepiness Scale; BDI = Beck Depression Inventory; ASRS = adult ADHD self-report scale symptom checklist (In = Inattentive, 
Hy = Hyperactive).  
* p <0.05 
** p <0.01 
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Figure legend 
 
Figure 1. Representation of the sequence of events in each trial of the attention network test (ANT) 
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Figure 2.  Box Plot of the three attentional network score in narcolepsy type 1 (NT1), Narcolepsy 
type 2 (NT2)  and controls. 
 
* p = 0.005 
** p <0.01 
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Figure 3. Mean RTs (ms) of the cue and flanker conditions relevant for each attentional networks 
of narcolepsy type 1 (NT1), Narcolepsy type 2 (NT2)  and controls. 
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Chapter 5 
General Discussion 
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In this dissertation, the three experimental chapters were designed to identify behavioral biomarker 
of Type 1 Narcolepsy as well as attentional deficits in patients with or without hypocretin-
deficiency. In Chapter 2 we described a new features of the nycthemeral disruption presented by 
adult type 1 narcolepsy patients. 
Our approach focused on prolonged monitoring of motor activity by means of actigraphy, a watch-
like device, that allows to record raw activity data for extended time. 
Capitalizing on the main advantage of actigraphy i.e. the concurrent  documentation of both sleep 
and wakefulness, we computed a discriminant score that accurately identify NT1 patients, not only 
relative to controls, but also compared to another central disorder of hypersomnolence (Idiopathic 
Hypersomia, IH) with an high overlapping of clinical features. 
In Chapter 3 we finely investigated the features of circadian rest-activity rhythm of NT1 children, 
by applying spectral analysis and permutation test on motor activity data. 
We described a new proper pattern of motor activity in NT1 children, with blunted motor activity in 
the first afternoon and enhanced motor activity throughout the night. We confirmed that actigraphic 
assessment is highly specific for NT1 also in children close to disease onset. Moreover, we show 
that actigraphic profile is a promising information able to objectively stratify disease burden. 
In Chapter 4 we described new findings on the attentional deficits of narcoleptic patients (NT1 and 
NT2) and their relationship with sleepiness, anxiety and depression. Moreover, we firstly reported 
and increased frequency of ADHD symptoms in adult patients with  that  NT1 and NT2.  
Our results highlighted that both cognitive deficits and psychiatric comorbidity have to be carefully 
assessed  in clinical evaluation of narcolepsy spectrum disorder. 
The aims of the current dissertation were as follows and are discussed separately below: 
• Identify behavioral biomarker for Type 1 Narcolepsy  
• Characterize attentional performances of patients with Type 1 and Type 2 Narcolepsy 
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Behavioral Biomarker for Type 1 Narcolepsy 
 
Narcolepsy is one of the most common causes of chronic sleepiness, affecting about 1 in 2000 
people. Despite the frequency of narcolepsy, the average time from the onset of symptoms to 
diagnosis is 5 to 15 years, and narcolepsy often remains undiagnosed in as many as half of all 
affected people. Narcolepsy is often challenging to diagnose and remains and many clinicians are 
unfamiliar with this disorder. Fortunately, awareness of narcolepsy and other sleep disorders is 
increasing, and over the past several years researchers have made great progress in understanding 
narcolepsy. However, to date no screening approach has been identified for this disorder and this is 
one of the major factor associated with diagnostic delay. 
NT1, have a prominent impact on quality of life since its early stages, a delayed diagnosis and 
consequently a delay in beginning appropriate pharmacological and behavioral treatments 
markedly heighten disease burden. 
In Chapter 2 we have demonstrated that actigraphy display unique potentialities in the assessment 
of patients suffering from central disorders of hypersomnolence and in particular NT1 
NT1 is indeed a disease affecting the whole 24-hr system, nocturnal sleep cannot be consolidated 
for long periods and sleep episodes recur several times during the day. 
Sleep laboratory assessment usually focus on assessment of nocturnal sleep (by mean of PSG) or 
diurnal sleepiness (by means of MSLT), however both test can be performed only during 
hospitalization, moreover they provide a highly-accurate description of sleep but in a very limited 
time span (maximum 24-hr) 
Among all devices used to assess sleep, actigraphy is the only that can concurrently document both 
sleep wakefulness for extended time period. 
Indeed focusing assessment of both diurnal and nocturnal period actigraphy well-render this 
peculiar nycthemeral rhythm disruption. The actigraphic profile of NT1 patients is very specific and 
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characterized by a major nocturnal sleep disruption with prolonged awakenings and enhanced motor 
activity and recurrent daytime naps. Clear-cut differences in actigraphic parameter computed have 
been found (with CI not overlapping with 0), accordingly we tested the possibility to classify 
subjects by means of these parameters (one or more, in association).  
We showed that the combined use of both nocturnal (estimated SMA, estimated Awk) and diurnal 
(estimated NapD) parameters performed better in NT1 cases (87% correctly classified) than any 
single actigraphic measure. 
Indeed, these parameters reflect two intrinsic features of NT1, namely disrupted nocturnal sleep 
(estimated Awk, estimated SMA) and hypersomnolence (estimated NapD). We acknowledge that a 
classification rule that relies simultaneously on daytime and nighttime measures works well in 
patients with a severe disruptions of sleep and wakefulness (NT1) otherwise when only diurnal 
period is disrupted (IH indeed display preserved nocturnal sleep) the discriminant validity of 
actigraphy did not reach acceptable level and probably should be integrated with other sources of 
data from the diurnal period. 
Upon showing the actigraphic ability of render this peculiar 24-hr disruption (Chapter 2), we 
question whether this peculiar disruption is already noticeable by means of actigraphy in early 
stages of the disease. We therefore applied actigraphic evaluation to NT1 children as close as 
possible to disease onset (Chapter 3). 
We focused more deeply in analyses of circadian pattern of motor activity, applying techniques 
proper of EEG analyses and physic to raw actigraphic signal. We enrolled NT1 children and healthy 
controls during the school period, and assess their sleep-wake behavior across seven days. NT1 
children systematically display at least one diurnal nap immediately after the end of school time, 
and present sustained motor activity during sleep that is severely fragmented by numerous and 
prolonged awakenings. Moreover, we firstly showed evaluation that increased BMI, high subjective 
sleepiness, and low CSF-hcrt-1 levels were associated with the severity of nycthemeral disruption in 
NT1 children. Actigraphy allowed us to document long-lasting diurnal sleep episodes that are often 
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reported in childhood NT1.The standard diagnostic approach, based on the nocturnal 
polysomnography followed by the MSLT, allows a proper neurophysiological diagnosis with high 
sensitivity and specificity, but does not give insight into this very common aspect of NT1 
hypersomnolence. 
This findings have several clinical implication, the ecological description of nycthemeral disruption 
could be used to plan supportive strategies and tailor personalized treatments. Behavioral treatment 
(i.e. regularly scheduled naps)  is a major management strategy for NT1, actigraphy can be used to 
objectively assess, and possibly adjust, the napping schedule.  
Finally with correlation analyses, we pointed to the possibility of objectively stratify disease 
severity in the apparently uniform clinical picture of NT1 taking into account clinical, 
anthropometric, neurophysiological and motor activity features. 
 
Attention deficits and ADHD symptoms in Narcolepsy-spectrum disorder 
 
Attention performances of Narcoleptic patients (either NT1 and NT2) are presence of ADHD and 
OCD comorbidity are described in Chapter 4. 
Narcolepsy is a severely disabling disease, which limits patients in many aspects of everyday life 
As a consequence, health-related quality of life is reported to be poor. In particular, EDS is found to 
impact on well-being and to impair physical, emotional and social functioning. Depressive 
symptoms and anxiety disorders have also been described in association with narcolepsy 
People with narcolepsy often complain about difficulties with memory, learning and concentration 
However, research results are heterogeneous as to whether individuals with narcolepsy have 
objective memory impairments: some studies have pointed to an intact performance of patients with 
narcolepsy in standard memory tests, others have found only modest memory impairments. 
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There is more-consistent evidence that patients with narcolepsy have attention and executive 
function deficits, which could explain their perceptions of memory deficits and, to some 
extent, their difficulties in some daily life activities (e.g. driving). 
We showed that compared to good sleepers and patients with Narcolepsy without hypocretin-
deficiency (NT2), hypocretin-deficient Narcoleptic patients (NT1) present a specific profile of 
attentional impairments. 
Our findings for the ANT showed that the overall RTs was longer in Narcoleptic patients (either 
type 1 and type 2) compared to healthy controls. Results from Chapter 4 also revealed difference in 
alerting network functioning of NT1 patients relative to controls, while no differences were 
observed in the functioning of orienting and executive control network. NT1 patients shows  an 
aberrant functioning of alerting networks, with a greater differences of RTs between trials with and 
without warning-cue. 
The peculiar attentional deficit of NT1 demonstrated herewith, provide new physiological insight 
on the nature of cognitive in narcolepsy. Our data showed that in NT1 the tonic component of 
alerting process is highly instable; this made necessary monitoring and compensation strategies and 
lead to a reduction of free processing resources and affecting thereby the perception of memory 
deterioration often clinically reported by patients.  
Comparing patients with NT1 and NT2, with comparable levels of subjective sleepiness and MSLT 
sleep latency, but different biochemical profile, we were able to control for the influence of 
sleepiness and hypocretin-deficiency on attentional performance in the clinical groups. 
The clear-cut group differences, evident even in the proportional (Pro) network score, indicate the 
peculiar impairments of alerting network is attributable to  the lack of hypocretinergic neurons. 
Analyzing self-reported measure we showed that patients with narcolepsy (either type 1 and type 2) 
rated their levels of attention in everyday situations to be relatively poor. 
Compared with healthy adults, they reported an higher frequency of ADHD Inattentive symptoms; 
moreover, patients with NT1 reported also and increased frequency of ADHD 
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hyperactive/impulsive symptoms. To our knowledge this is the first investigation aimed to explore 
the presence of comorbid ADHD in adult narcoleptic patients, our data disclose that a significant 
portion of NT1 patients (54%) showed ADHD scores in a standardized questionnaire above the 
clinical cut-off. In variance to previous investigations only a few patients with narcolepsy showed 
symptoms of increased anxiety, while compared with adult controls both clinical group reported 
greater levels of subjective sleepiness. In NT1 patients the severity of depressive complains were 
positively correlated with levels of subjective sleepiness and severity of ADHD symptoms, 
moreover a negative relationship between ESS score and alerting network efficiency was 
observable in NT1. Accordingly,  our study showed that not only sleepiness momentary but also 
ADHD symptoms have an major impact on depressive complains reported by patients with 
narcolepsy. 
This finding is of interest to the clinicians involved in the patients’ treatment and counselling. 
Narcolepsy is a major organic disease with an important impact of increased  sleepiness on 
daily cognition, whether the patients are depressed or not. However, depression may have an 
additional effect on the patients’ subjectively perceived cognitive deficits. 
Careful screening for ADHD comorbidity and eventually appropriate treatments may thus alleviate 
the patients’ burden. In some cases, it may be appropriate to discuss with the patients that 
their subjectively perceived cognitive deficits might be attributed to both sleepiness and depression 
rather than to objective cognitive decline. 
Knowing about the relationship between sleepiness, mood and attention deficits may prevent 
patients from taking wrong decisions (e.g. about their professional life). The present study 
also underlines the necessity to perform objective neuropsychological tests, which may also offer 
the possibility to objectively assess the effectiveness of pharmacological treatments on attentional 
impairments. 
 
 
